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A B S T R A C T
Background
The use of combination antiretroviral therapy (cART) comprising three antiretroviral medications from at least two classes of drugs is
the current standard treatment for HIV infection in adults and children. Current World Health Organization (WHO) guidelines for
antiretroviral therapy recommend early treatment regardless of immunologic thresholds or the clinical condition for all infants (less
than one years of age) and children under the age of two years. For children aged two to five years current WHO guidelines recommend
(based on low quality evidence) that clinical and immunological thresholds be used to identify those who need to start cART (advanced
clinical stage or CD4 counts ≤ 750 cells/mm3 or per cent CD4 ≤ 25%). This Cochrane review will inform the current available
evidence regarding the optimal time for treatment initiation in children aged two to five years with the goal of informing the revision
of WHO 2013 recommendations on when to initiate cART in children.
Objectives
To assess the evidence for the optimal time to initiate cART in treatment-naive, HIV-infected children aged 2 to 5 years.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, the AEGIS conference database,
specific relevant conferences, www.clinicaltrials.gov, theWorld Health Organization International Clinical Trials Registry platform and
reference lists of articles. The date of the most recent search was 30 September 2012.
Selection criteria
Randomised controlled trials (RCTs) that compared immediate with deferred initiation of cART, and prospective cohort studies which
followed children from enrolment to start of cART and on cART.
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Data collection and analysis
Two review authors considered studies for inclusion in the review, assessed the risk of bias, and extracted data on the primary outcome
of death from all causes and several secondary outcomes, including incidence of CDC category C and B clinical events and per cent
CD4 cells (CD4%) at study end. For RCTs we calculated relative risks (RR) or mean differences with 95% confidence intervals (95%
CI). For cohort data, we extracted relative risks with 95% CI from adjusted analyses. We combined results from RCTs using a random
effects model and examined statistical heterogeneity.
Main results
Two RCTs in HIV-positive children aged 1 to 12 years were identified. One trial was the pilot study for the larger second trial and both
compared initiation of cART regardless of clinical-immunological conditions with deferred initiation until per cent CD4 dropped to
<15%. The two trials were conducted in Thailand, and Thailand and Cambodia, respectively. Unpublished analyses of the 122 children
enrolled at ages 2 to 5 years were included in this review. There was one death in the immediate cART group and no deaths in the
deferred group (RR 2.9; 95% CI 0.12 to 68.9). In the subgroup analysis of children aged 24 to 59 months, there was one CDC C event
in each group (RR 0.96; 95% CI 0.06 to 14.87) and 8 and 11 CDC B events in the immediate and deferred groups respectively (RR
0.95; 95% CI 0.24 to 3.73). In this subgroup, the mean difference in CD4 per cent at study end was 5.9% (95% CI 2.7 to 9.1). One
cohort study from South Africa, which compared the effect of delaying cART for up to 60 days in 573 HIV-positive children starting
tuberculosis treatment (median age 3.5 years), was also included. The adjusted hazard ratios for the effect on mortality of delaying ART
for more than 60 days was 1.32 (95% CI 0.55 to 3.16).
Authors’ conclusions
This systematic review shows that there is insufficient evidence from clinical trials in support of either early or CD4-guided initiation
of ART in HIV-infected children aged 2 to 5 years. Programmatic issues such as the retention in care of children in ART programmes
in resource-limited settings will need to be considered when formulating WHO 2013 recommendations.
P L A I N L A N G U A G E S U M M A R Y
When is the best time to start antiretroviral therapy in children 2 to 5 years old who have HIV infection?
Antiretroviral combination therapy (cART) has been shown to be effective in slowing down the progression of AIDS and in reducing
HIV-related illnesses and death. In infants and children who are diagnosed with HIV infection and are below two years of age the
World Health Organization (WHO) recommends that cART should be started immediately. In children aged 2 to 5 years the WHO
2010 recommendations stated that treatment should be started when the body’s defence system has started to weaken (as indicated
by a decline in a child’s CD4 cell count) or complications have occurred. This systematic review was undertaken to help inform the
2013 WHO guidelines which aimed to revise the recommendations of when to start therapy in 2 to 5 years old children. The authors
identified two randomised controlled trials (RCTs) that compared immediate with deferred initiation of cART in HIV-positive children
aged 1 to 12 years in Thailand or Cambodia. Additional analyses of 122 children enrolled in the two studies at ages 2 to 5 years were
made available for this review. A cohort study from South Africa in HIV-positive children (median age 3.5 years) starting tuberculosis
treatment and ART was also included. Results showed that we still lack enough evidence to determine whether early or late initiation of
cART is best in children aged 2 to 5 years. The authors recognized the lack of evidence but highlighted the potential value of simplifying
WHO recommendations to start cART in all children below five years with the goal of providing programmatic advantage to treatment
programmes in resource-limited settings.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
IMMEDIATE initiation of cART compared to DEFERRED initiation of cART for HIV-positive, treatment-naive children aged 24 to 59 months (2 to 5 years old)
Patient or population: HIV-positive, treatment-naive children aged one to 12 years old
Settings: Thailand and Cambodia
Intervention: IMMEDIATE initiation of cART
Comparison: DEFERRED initiation of cART
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
DEFERRED initiation of
cART
IMMEDIATE initiation of
cART
Death 0 per 1000 0 per 1000
(0 to 0)
RR 3
(0.12 to 73.06)
343
(2 studies)
⊕©©©
very low1,2,3
CDC Category C disease
(number of children)
Follow-up: 144 weeks
12 per 1000 18 per 1000
(3 to 105)
RR 1.5
(0.25 to 8.85)
343
(2 studies)
⊕©©©
very low1,2,4
CDC Category B disease
(numbers of children)
Peto Odds Ratio
189 per 1000 141 per 1000
(83 to 225)
OR 0.7
(0.39 to 1.24)
343
(2 studies)
⊕©©©
very low1,2,4,5
Proportion of children on
ART with HIV-RNA <50
copies/ml (Copy)
815 per 1000 783 per 1000
(685 to 889)
RR 0.96
(0.84 to 1.09)
238
(2 studies)
⊕⊕©©
low1,2,4
Weight gain per year in
kg
The mean weight gain per
year in kg in the interven-
tion groups was
0.1 higher
(0.16 lower to 0.36
higher)
300
(1 study)
⊕⊕©©
low1,2,6,7
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Height gain per year in
cm
The mean height gain per
year in cm in the interven-
tion groups was
0.5 higher
(0.2 to 0.8 higher)
300
(1 study)
⊕⊕©©
low1,2,6,7
Standardized score on
Beery VMI at 144 weeks
The mean standardized
score on Beery VMI at
144 weeks in the inter-
vention groups was
1.4 lower
(4.7 lower to 1.9 higher)
272
(1 study)
⊕⊕©©
low1,2,6,7
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
Patient or population:
HIV-positive, treatment-
naive children aged 24 to
59 months (2 to 5 years
old)
Settings: Thailand and
Cambodia
Intervention: IMMEDI-
ATE initiation of cART
Comparison: DEFERRED
initiation of cART
Outcomes Illustrative comparative
risks* (95% CI)
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
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DEFERRED initiation of
cART
1 As the trials were open-label neither participants nor caregivers were blinded. However outcome assessors were blinded in the PREDICT
trial. Attrition was low in both trials. Information on the randomisation procedure was lacking in Ananworanich 2008. However, given
that this trial is relatively small, we judged the overall risk of bias to be low for the two trials together.
2 The age group included in the trials ranged from one year to 12 years old and did not focus on the specific population focus of this
review: ages 24 to 59 months.
3 The confidence interval is very large and the event rate very low. There was only one death.
4 The event rate was very low and the overall sample size is also small.
5 The trials reported conflicting results and there was substantial unexplained heterogeneity.
6 The results are from only one trial so consistency cannot be adequately gauged.
7 The sample size is less than 400 and according to the GRADE approach imprecision is present when continuous outcomes are
compared in samples less than 400.
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B A C K G R O U N D
Description of the condition
The World Health Organization (WHO) estimated that in 2011
there were 2.5 million (2.24 to 2.8 million) people who became
newly infected with HIV (UNAIDS 2012). Of these, an estimated
330 000 [200 000-270 000] were children less than 15 years old.
This is a 24% decrease in global figures since 2009 and can largely
be attributed to the expansion in access to services for preventing
mother-to-child transmission of HIV, the primary route of HIV
acquisition in children.
Sub-Saharan Africa is disproportionately represented in the epi-
demic with 69% of the global total of people living with HIV
(UNAIDS 2012). An estimated 90% of the world’s children living
with HIV live in sub-Saharan Africa. At the end of 2011, 54% of
the 14.2 million people (adults and children) in need of treatment
in low- and middle-income countries were receiving antiretroviral
therapy (UNAIDS 2012). However, in sub-Saharan Africa, an-
tiretroviral therapy coverage of children in the region is far below
the global average, at just 28% (25 - 31%).
Description of the intervention
The use of combination antiretroviral therapy (cART) compris-
ing three antiretroviral medications from at least two classes of
drugs is the current standard treatment forHIV infection in adults
and children (WHO 2010b). While the availability of cART has
changed the course of paediatric HIV infection with a notable
reduction in mortality observed over long-term follow-up (Patel
2008), late initiation of cART and poor retention in care remain
significant challenges in resource-limited settings (Fenner 2010).
Determining the optimal timing to initiate cART in children
is challenging for several reasons. As children grow, the organs
involved in drug metabolism mature. As a result, the pharma-
cokinetic environment is dynamic and treatment needs to be ad-
justed according to age and weight (Heidari 2012). Ifmalnutrition
is present or treatment for co-infections such as tuberculosis or
malaria is required, the pharmacokinetics of drugs may be further
altered (Heidari 2012). Markers of disease progression, such as
the CD4 count, are unreliable in young children limiting disease
monitoring (Prendergast 2012). Given that treatment is life-long,
the risk of drug resistance is prolonged and the potential for long-
term toxicity exists (Heidari 2012). Determining the optimal time
to initiate cART in children is therefore critical.
Current World Health Organization (WHO) guidelines for an-
tiretroviral therapy recommend early treatment regardless of im-
munologic or clinical thresholds for all infants (less than one year
of age) and children under the age of two years (WHO 2010b).
The decision to initiate early treatment in infants was based on
the evidence provided by the Children with HIV Early Antiretro-
viral Therapy trial (CHER) (Violari 2008) and supported by a
Cochrane review (Penazzato 2012). The subsequent extension of
this guideline to children under the age of two years was developed
with the goal of improving retention and based on the high risk
of disease progression and death and the poor predictive value of
immunological markers in this age group (Prendergast 2012).
For children aged 24 to 59 months (two to five years) current
WHO guidelines recommend that clinical and immunological
thresholds be used to identify those children aged 24 to 59months
who need to start cART (WHO 2010b). Specifically, treatment
should be initiated for all HIV-infected children with WHOHIV
clinical stages 3 and 4, irrespective of CD4 count. In children
aged 24 to 59 months (2 to 5 years in age), cART should be
initiated when CD4 counts <= 750 cells/mm3 or %CD4 <= 25%,
irrespective of the WHO clinical stage. These recommendations
are acknowledged to be based on low or very low quality evidence.
Why it is important to do this review
The World Health Organization (WHO) Antiretroviral Therapy
Guideline is the main normative cART tool at global level and
is used by regional and national programme managers to develop
national treatment guidelines. The first guideline was produced
in 2002 (WHO 2002), then revised in 2003 (WHO 2003). In
2006, and then again in 2010, separate sets of recommendations
- one for adults and adolescents (WHO 2006a; WHO 2010a)
and another for children (WHO 2006b; WHO 2010b) - were
published as two guideline documents. In 2011, WHO/UNAIDS
established a new initiative,Treatment 2.0, that advocates for the
development and expanded use of more simplified, less toxic drug
regimens, with high barriers to drug resistance, that require min-
imal clinical monitoring while maintaining therapeutic efficacy
(WHO 2011b). Treatment 2.0 aims to expand access to treatment
and applies equally to both adults and children. In this context,
revising WHO recommendations will require re-examining the
evidence for when to start cART in infants and children. While
a completed Cochrane review has focused on the effectiveness of
cART in children aged under two years (Penazzato 2012), this
Cochrane review will inform the revision of the WHO antiretro-
viral therapy guidelines specifically for when to initiate cART in
children aged two to five years old.
O B J E C T I V E S
To assess the evidence for the optimal time to initiate cART in
treatment-naive, HIV-infected children aged 24 to 59 months (2
to 5 years old).
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M E T H O D S
Criteria for considering studies for this review
Types of studies
1. Randomised controlled trials (RCTs)
2. Prospective cohort studies which followed children from
enrolment to start of cARTand for at least a median of one year
on cART
Non-comparative cohort studies in which children are all com-
menced on cART at enrolment regardless of clinical-immunolog-
ical condition were excluded.
Types of participants
Children with confirmed HIV infection (HIV PCR-positive if
diagnosed at age<18 months or HIV ELISA-positive if diagnosed
after 18 months of age) aged between 24 and 59 months (two to
five years in age) who are treatment-naïve (except for exposure to
drugs to preventmother-to-child transmission) at commencement
of the study.
Studies which included the above age group within a larger age
range were included. We contacted trial authors to obtain the
specific age range 24 to 59 months.
Studies in children with tuberculosis and other opportunistic ill-
nesses were included.
Studies focused only on infants (less than one year in age) were ex-
cluded. These are included in another Cochrane review (Penazzato
2012).
ForRCTs, at study entry, childrenmustnothave fulfilled guideline
criteria for starting antiretroviral treatment recommended at the
time of the study.
Types of interventions
Studies which compare initiating triple cART at different thresh-
olds.
1. In RCTs, the intervention group must have initiated triple
cART irrespective of clinical stage or CD4 count (immediate
initiation). The control group must have initiated cART using
clinical and immunological criteria to determine the time for
initiation (deferred initiation) as recommended at the time of the
study.
2. In cohort studies, children starting triple cART at different
CD4 percent or CD4 counts must have been compared. Analysis
must have included adjustment for time-dependent confounding
and lead-time bias specifically to evaluate the effect of timing of
cART initiation on outcomes.
Types of outcome measures
Primary outcomes
Mortality (all-cause)
Secondary outcomes
1. Clinical occurrence of new HIV-related events (death or
AIDS-defining illness)
2. Time to event of new HIV-related events (death or AIDS-
defining illness)
3. Immunological response (change in mean or median CD4+
cell count (mean or median relative change (percent) or mean or
median absolute change, compared with baseline, and standard
deviation or range as appropriate)
4. Adherence
5. Loss-to-follow-up
6. Virologic response (proportion of patients achieving and
maintaining an undetectable viral load, as defined by the
investigators; change in HIV-RNA levels (mean relative change
(percent) or mean absolute change, compared with baseline, and
standard deviations)
7. HIV drug resistance
Adverse events
Severe adverse events were reported. If classified according to grade
1 to 4 of the Adverse Event Toxicity Scale, we reported grade 3 and
4 events. Using this scale, grade 1 and 2 denote mild to moderate
symptoms, grade 3 denote serious symptoms and grade 4 denote
life-threatening events requiring significant clinical intervention.
Grade 5 denotes death (DAIDS 2009).
Search methods for identification of studies
See: HIV/AIDS Collaborative Review Group search strategy. The
search aimed to be comprehensive and included published and
unpublished studies and was not limited to any language.
Electronic searches
We developed the search strategy with the assistance of the HIV/
AIDS Review Group Trials Search Co-ordinator. We formulated
a comprehensive and exhaustive search strategy in an attempt to
identify all relevant randomised controlled trials and cohort stud-
ies regardless of language or publication status (published, unpub-
lished, in press, and in progress). Full details of theCochraneHIV/
AIDS Review Group methods and the journals hand-searched are
published in the section on Collaborative Review Groups inThe
Cochrane Library.
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For the RCT search, we combined the RCT strategy developed by
The Cochrane Collaboration and detailed in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2009) in
combination with terms specific to initiation of antiretroviral ther-
apy and children. The search was iterative and a number of trial
searches were run first as there are no database-specific terms for
’initiation’ of treatment and so we used many free text terms. This
increased the yield and hence the search sensitivity but reduced
the precision.
As there are no validated search strategies for cohort studies, our
strategy was informed by the cohort strategy developed by BMJ
Clinical Evidence (http://clinicalevidence.bmj.com/x/set/static/
ebm/learn/665076.html).
We searched the following databases:
1. Journal databases
For RCT Identification:
• Medline via Pubmed - see search strategy conducted on 27
June 2012 in Appendix 1
• EmBase - see search strategy conducted on 27 June 2012 in
Appendix 2
• Cochrane Central Register of Controlled Trials
(CENTRAL) - see search strategy conducted on 27 June 2012 in
Appendix 3
For cohort identification:
• Medline via Pubmed - see search strategy conducted on 11
September 2012 in Appendix 4
• EmBase - see search strategy conducted on 11 September
2012 in Appendix 5
2. Conference databases:
We searched the AEGIS database (www.aegis.org) on 24 July
2012. www.aegis.org contained abstracts from the following ma-
jor related conferences: 1st-5th International AIDS Society (IAS)
Conference on HIV Pathogenesis and Treatment and Prevention
(2001-2009); 10th-17th International AIDS Conference (IAC)
(1994-2008); 1st-16th Conference of Retrovirus andOpportunis-
tic Infections (CROI) (1994-2009); US National HIV Preven-
tion Conference; 7th-14th British HIV Association (2001-2008);
and 8th-9th European AIDS Clinical Society Conference (2001,
2003).
AEGIS does not allow for multiple search strings and so, in order
to search the database effectively, a separate search was done for
relevant terms combined with the term [random*] to identify rel-
evant trials:
ANTIRETROVIRAL* AND RANDOM* AND (child* OR in-
fant* OR toddler* OR pediatric* OR paediatric*)
The more recent conferences (up to 2012) were covered by search-
ing the conference web-sites of the International AIDS Society, the
International AIDS Conference and the CROI. The abstracts of
the 1st, 2nd, 3rd and 4th International Workshop on HIV Pedi-
atrics were hand-searched in Reviews in Antiviral Therapy & Infec-
tious Diseases where they are published following the conference.
3. Ongoing trials:
To identify ongoing RCTs we searched ClinicalTrials.gov (http:/
/clinicaltrials.gov/) on 9 July 2012 and the World Health Orga-
nization International Clinical Trials Registry Platform (http://
apps.who.int/trialsearch/) on 12 July 2012.
Searching other resources
We also checked the reference lists of all studies identified by the
above methods and examined any systematic reviews, meta-anal-
yses, or guidelines we identified during the search process for ref-
erences.
Wewere in close contactwith individual researchersworking in the
field, and policymakers based in inter-governmental organizations
including theWorldHealthOrganization (WHO) andUNAIDS.
We did not conduct hand-searching of specific journals other than
those searched by the Cochrane HIV/AIDS Review Group and
already included in CENTRAL.
Data collection and analysis
Selection of studies
For the RCT search of journal databases, NS and ME read the
titles, abstracts and descriptor terms of all downloaded material
from the electronic searches to identify potentially eligible reports.
Full text articles were be obtained for all citations identified as po-
tentially eligible andNS andME independently inspected these to
establish the relevance of the article according to the pre-specified
criteria. Where there was any uncertainty as to the eligibility of
the record, we obtained the full article.
NS and ME independently applied the inclusion criteria, and any
differences arising were resolved by discussions with the third re-
viewer, MD. Studies were reviewed for relevance based on study
design, types of participants, exposures and outcome measures.
For the additional cohort search of journal databases, NS read the
titles, abstracts and descriptor terms of all downloaded material
from the electronic searches to identify potentially eligible reports.
After identification of potentially eligible articles, ME checked
these and any uncertainty was discussed and resolved by discus-
sions with the third review author, MD.
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For all conference abstract searching, NS read the titles, abstracts
and descriptor terms of all downloaded material and manually
hand-searched conference abstract books when it was not possible
to search the web-site effectively.NS contacted authors of abstracts
to confirmwhether the study had been published and/or whether a
final reportwas available. Abstractswhich described studies already
identified in the electronic searches were linked to these.
Data extraction and management
NS independently extracted data into a standardised data extrac-
tion form. ME checked the data extraction independently. The
following characteristics were extracted from each included study.
• Administrative details: Trial or study identification number;
author(s); published or unpublished; year of publication;
number of studies included in paper; year in which study was
conducted; details of other relevant papers cited;
• Details of the study: Study design; type, duration and
completeness of follow-up; country and location of study (e.g.
higher-income vs. lower-income country); informed consent and
ethics approval;
• Details of participants: Setting, numbers, relevant baseline
characteristics including CD4 count and viral load;age range;
• Details of intervention: CD4 count and age at which
treatment was initiated; drug combinations; additional co-
interventions; and
• Details of outcomes: Mortality; HIV-related morbidity;
HIV-RNA viral load measurements and proposed levels for
suppression, as defined by the authors; clinical disease
progression; CD4+ cell counts; adverse events and toxicity.
• Details of the analysis: For RCTs, details of the type of
analysis (intention-to-treat or per protocol); for cohort studies,
details of the type of adjustment performed in the analysis.
Assessment of risk of bias in included studies
For both RCTs and cohort studies, NS and ME independently
examined the components of each included study for risk of bias
using a standard form. This includes information on the sequence
generation, allocation concealment, blinding (participants, per-
sonnel and outcome assessor), incomplete outcome data, selective
outcome reporting and other sources of bias. The methodolog-
ical components of the trials were assessed and classified as at a
high, low or unclear risk of bias as per the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2009). Where
differences arose, these were resolved by discussions with the third
reviewer, MD.
Sequence generation
• Adequate: investigators described a random component in
the sequence generation process such as the use of random
number table, coin tossing, cards or envelops shuffling etc
• Inadequate: investigators described a non-random
component in the sequence generation process such as the use of
odd or even date of birth, algorithm based on the day/date of
birth, hospital or clinic record number
• Unclear: insufficient information to permit judgment of the
sequence generation process
Allocation concealment
• Adequate: participants and the investigators enrolling
participants cannot foresee assignment, e.g. central allocation; or
sequentially numbered, opaque, sealed envelopes.
• Inadequate: participants and investigators enrolling
participants can foresee upcoming assignment, e.g. an open
random allocation schedule (e.g. a list of random numbers); or
envelopes were unsealed or nonopaque or not sequentially
numbered
• Unclear: insufficient information to permit judgment of the
allocation concealment or the method not described
Blinding
• Adequate: blinding of the participants, key study personnel
and outcome assessor, and unlikely that the blinding could have
been broken. Or lack of blinding unlikely to introduce bias. No
blinding in the situation where non-blinding is not likely to
introduce bias.
• Inadequate: no blinding, incomplete blinding and the
outcome is likely to be influenced by lack of blinding
• Unclear: insufficient information to permit judgment of
adequacy or otherwise of the blinding
Incomplete outcome data
• Adequate: no missing outcome data, reasons for missing
outcome data unlikely to be related to true outcome, or missing
outcome data balanced in number across groups
• Inadequate: reason for missing outcome data likely to be
related to true outcome, with either imbalance in number across
groups or reasons for missing data
• Unclear: insufficient reporting of attrition or exclusions
Selective Reporting
• Adequate: a protocol is available which clearly states the
primary outcome as the same as in the final trial report
• Inadequate: the primary outcome differs between the
protocol and final trial report
• Unclear: no trial protocol is available or there is insufficient
reporting to determine if selective reporting is present
Control of time-dependent confounding (cohort studies only)
The use of standard regression models for the analysis of cohort
studies with time-updated measurements may result in biased es-
timates of treatment effects if time-dependent confounders are
present (Robins 2000). In cohorts of HIV-infected patients CD4
cell percentage or CD4 cell counts are measured regularly to assess
the patients’ eligibility for cART and, once on cART, to monitor
therapy. CD4 count is a time-dependent confounder because it
predicts both future cART and outcome, and is influenced by past
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antiretroviral therapy. In other words, CD4 count is on the causal
pathway between treatment and the outcome.
• Adequate: appropriate methods were used to control for
time-dependent confounding (e.g. marginal structural models)
• Inadequate: there was no control for time-dependent
confounding
• Unclear: insufficient reporting to determine whether there
was control for time-dependent confounding
Other forms of bias
• Adequate: there is no evidence of bias from other sources
• Inadequate: there is potential bias present from other
sources (e.g. early stopping of trial, fraudulent activity, extreme
baseline imbalance or bias related to specific study design)
• Unclear: insufficient information to permit judgment of
adequacy or otherwise of other forms of bias
Measures of treatment effect
Data analysis was conducted using (RevMan) version 5.1.7.
For RCT data, outcome measures for dichotomous data (e.g.
death, virological suppression) were calculated as relative risks with
95% confidence intervals. For continuous data (e.g. CD4+ cell
counts, HIV-RNA viral loads) we calculated the mean difference
and standard deviation where means were reported. Where medi-
ans and ranges were reported, we extracted the data directly from
the report.
For cohort data, we reported on the adjusted analysis using the
estimate of effect reported in the study. Where the adjusted esti-
mate of effect was reported with 95% Confidence Intervals (CI),
we calculated the Standard Error in order to enter the data into
RevMan, using the following formula for ratio measures:
lower limit = ln(lower confidence limit given for HR)
upper limit = ln(upper confidence limit given for HR)
intervention effect estimate = lnHR
SE = (upper limit - lower limit) / 3.92
Unit of analysis issues
We did not anticipate cluster or cross-over trials, with the poten-
tial for unit of analysis issues, being conducted to investigate this
question.
Dealing with missing data
Where data was missing or required clarification, we contacted
study authors to request additional data. Should this not have been
possible, we would have stated explicitly where calculations were
based on assumptions regarding missing data.
In trialswhich includedparticipants fromwithin a larger age range,
we contacted study authors to obtain the specific age range 24 to
59 months.
Assessment of heterogeneity
Where RCTs were found to bemethodologically or clinically com-
parable, we pooled trial results in a meta-analysis. As we antici-
pated the presence of statistical heterogeneity we combined the
data using the random effects model throughout.
Only one cohort study was included in the review, so it was not
applicable to assess heterogeneity. In future updates of this review,
where cohort studies are found to bemethodologically or clinically
comparable, we will pool the results in a meta-analysis using the
generic inverse variance function inRevMan to allow adjusted data
to be used in the analysis. Aswe anticipate heterogeneity due to the
likelihood of different analytical techniques and different adjusted
variables, we will combine studies using the random effectsmodel.
For the RCT meta-analyses, we formally tested for statistical het-
erogeneity using the Chi-square test for statistical homogeneity
with a 10% level of significance as the cut-off. The amount of
any statistical heterogeneity was quantified using the I² statistic
(Higgins 2002).
Where studies do not have combinable outcomes, we provide the
data in a narrative form.
Data synthesis
For meta-analysis of RCTs, we combined the results and calcu-
lated the overall relative risk and 95% confidence intervals using
the Mantel-Haenszel random-effects model. For continuous data,
we combined the mean differences to calculate a weighted mean
difference and standard deviation, using the inverse-variance ran-
dom-effects model. Peto fixed-effects models were used in sensi-
tivity analyses. If time-to-event data is available in future updates,
we will combine the hazard ratios reported in the RCTs using the
inverse-variance random-effects model.
For cohort studies in future updates, we will combine the ad-
justed estimates of effects using the inverse-variance random-ef-
fects model.
Subgroup analysis and investigation of heterogeneity
We anticipated statistical heterogeneity due to differences be-
tween studies conducted in resource-constrained compared with
resource-rich settings, and planned to present the results according
to these sub-groups should this have been necessary.
We performed subgroup analyses restricted to children less than 5
years old who had a CD4 above 25% to best inform the current
(2012) WHO guideline processes.
Sensitivity analysis
For RCTs, we planned to explore the effect of study quality on the
results by excluding those studies where allocation concealment
was unclear or inadequate from themeta-analysis and assessing the
effect of this on the overall results. For cohort studies we planned
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to examine the effect of adjustments for confounding and in par-
ticular confounding by indication.
We also conducted meta-analyses using the Peto Odds Ratio in
addition to the RR for those comparisons where the event rate was
extremely low.
GRADE assessment
GradePro 2008 was used to create Summary of Findings and Evi-
dence Profile tables. GradePro software was developed as part of a
larger initiative led by the Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) Working Group.
GRADE offers a system for rating quality of evidence in sys-
tematic reviews and guidelines and grading strength of recom-
mendations in guidelines (Guyatt 2011). Use of GradePro within
a Cochrane systematic review facilitates the process of present-
ing and grading evidence transparently (http://ims.cochrane.org/
revman/other-resources/gradepro/about-gradepro).
In determining the level of evidence for each outcome, both the
efficacy results and the assessment of the risk of bias was integrated
into a final assessment of the level of evidence and full details of
the decision was provided in footnotes.
R E S U L T S
Description of studies
Results of the search
Electronic databases
1. Journal databases
RCT studies
Using the RCT string, the PUBMED search yielded 914 records,
the EMBASE search yielded 616 records and the CENTRAL
search yielded 127 records. After deduplication using ProCite soft-
ware, we screened 1475 records of which 54 were identified as
potentially eligible RCTs or cohort studies and the full texts were
obtained. See Figure 1.
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Figure 1. Study flow diagram of database yields using the RCT string
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Cohort studies
Using the additional cohort string, the PUBMED search yielded
130 records, and the EMBASE search yielded 950 records. These
were de-duplicated electronically using EndNote reference man-
agement software, and 33 duplicate records were removed prior
to manual checking of the remaining 1047 records. No studies in
addition to those already selected for full text review in the RCT
string search, were identified.
2. Conference databases
The www.aegis.com conference database search yielded 170
records of which 9 abstracts were selected for further assessment.
We also searched the conference web-sites for the following specific
conferences using a broad term ’child’:
• International AIDS Society 2009: 305 records identified of
which 16 were selected for further assessment
• International AIDS Society 2011:513 records identified of
which 15 were selected for further assessment
• International AIDS Conference 2012: 115 records
identified of which three were selected for further assessment; all
relevant sessions reviewed and no additional relevant records
identified
• CROI 2011: 69 records identified of which four were
selected for further assessment
• CROI 2012: 85 records identified of which four were
selected for further assessment
NS identified one study (Munyagwa 2012) from the conference
searches which was published after the date the electronic journal
database search. This study was excluded after an eligibility assess-
ment of the full text. No other studies identified in the conference
searching were in addition to those studies already reviewed in the
electronic database searches, or contained data which was relevant
to this review after complete data sets were obtained.We contacted
a total of five abstract authors to confirm whether their abstracts
contained the same data as that reported in publications.
3. Trials Registries
We searchedClinicalTrials.gov (http://clinicaltrials.gov/) on 9 July
2012 and retrieved 300 records of which 9 studies were selected
for further assessment.
We also searched the World Health Organization Interna-
tional Clinical Trials Registry Platform (http://apps.who.int/
trialsearch/) on 12 July 2012 and retrieved 12 records of which
one study was selected for further assessment.
None of the 21 studies assessedmet our inclusion criteria. in future
updates wewill capture the details of studiesmeeting our inclusion
criteria under Characteristics of ongoing studies.
Searching other resources
To supplement the electronic searching for conference databases,
we searched the following books of conference abstracts manually
during August and September 2012:
• CROI 2009: 2 records were identified for further assessment
• CROI 2010: 2 records were identified for further assessment
• 1st International Workshop on HIV Pediatrics (157
abstracts in total): 13 records identified for further assessment
• 2nd International Workshop on HIV Pediatrics (123
abstracts in total); 10 records identified for further assessment
• 3rd International Workshop on HIV Pediatrics (186
abstracts in total): 10 records identified for further assessment
• 4th International Workshop on HIV Pediatrics (200
abstracts in total); 5 records identified for further assessment
Through discussions with experts in the field and prior discussions
at conferences, we were aware of the PREDICT 2012 trial which
was published during the conduct of this review. This study was
reported in several of the above abstracts which we selected for
further assessment. No additional eligible studies were identified
in this way.
Included studies
RCTs
Following detailed eligibility assessment, two RCTs were identi-
fied as eligible (Ananworanich 2008; PREDICT 2012) from the
database searches. Additional searches of conferences and the trials
registries identified further abstracts which referred to these trials,
but no additional RCTs were identified in this way.
Details of the included studies are reported in the table
Characteristics of included studies.
In summary, two RCTs have evaluated the timing of initiating
cART in HIV-positive children aged 1 to 12 years, with CD4%
between 15 and 24%, and no CDC clinical stage C disease. cART
was initiated immediately on enrolment (IMMEDIATE group) or
deferred until theCD4%dropped to<15%(DEFERREDgroup).
The first trial (Ananworanich 2008) commenced in December
2001 and was designed as a small feasibility study prior to the
conduct of the larger trial which commenced in March 2006 (
PREDICT 2012). Both trials were conducted in south-east Asia:
Ananworanich 2008 was conducted in Thailand with a sample
size of 43 and PREDICT 2012 was conducted in Thailand and
Cambodia with a sample size of 300.
Of note, no trials have been conducted only in the specific
age group this review covers, viz. 24 to 59 months. In the
Ananworanich 2008 trial, the median age of participants was 4.8
years (IQR: 2.7 to 6.6) and in the PREDICT 2012 trial, 59%
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(88/150) and 55% (83/150) of children were aged 1 to 6 years in
the IMIMEDIATE and DEFERRED group respectively.
Cohorts
Following detailed eligibility assessment, several cohort studies
were selected for further assessment of the full-text. After discus-
sions between the co-authors, only one cohort study was deemed
eligible (Yotebieng 2010). See the details of the study in the table
Characteristics of included studies.
This study was an observational cohort of prospectively collected
routine data of children infected with tuberculosis (TB) and com-
pared the timing of initiation of cART using the number of days
since TB treatment was initiated, rather than based on CD4 cell
count or percentage. The cohort study commenced in April 2004
and took place in a paediatric clinic attached to a tertiary hospital
in Soweto, South Africa.
The study included 573 children aged 1 to 15 years with a median
age of 3.5 years (IQR: 1.4 - 6.8). The median length of follow-
up was 9.6 months (IQR: 1.9 to 23.1) which was less than the
median follow-up of one year stipulated in our review criteria for
study eligibility. However, after discussion among the co-authors,
we determined that given the paucity of data on ART initiation in
TB populations, we would include the study in the current review.
Excluded studies
After assessing the full-text articles 51 studies were excluded for
the reasons detailed in Figure 1.
Risk of bias in included studies
The detail of the risk of bias are presented in the Characteristics
of included studies and the graphical summary of the risk of bias
is represented in Figure 2; Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
RCTs
In Ananworanich 2008 we were unable to assess the risk of bias
in the randomisation and allocation procedures due to a lack of
reporting and judged the risk of bias as unclear. We judged the risk
of bias due to selection bias as low for the PREDICT 2012 trial as
the random sequence was generated by a computer and allocation
was done centrally.
Cohort
As Yotebieng 2010 is a cohort study, allocation was not done
randomly. The study is therefore at high risk of selection bias but
it was analysed in a way that will have reduced bias (mimicking a
randomised trial - see other sources of bias below).
Blinding
RCTs
Both trials were open-label and thus neither participants and their
caregivers nor personnel were blinded, potentially introducing a
high risk of performance bias.
In the Ananworanich 2008 trial we were not able to determine
whether outcomes were assessed in a blinded manner and we rated
the risk of bias as unclear. In PREDICT 2012, the primary out-
comes were assessed by an independent committee blinded to al-
location and the risk of detection bias was low.
Cohort
The personnel and caregivers were not blinded to whether the
children were receiving cART or not and we judged the risk of
performance bias as high.
Although the authors do not report on blinding for the two pri-
mary outcomes of death and virological suppression (in those pa-
tients receiving cART) or on how death was confirmed, we judged
the lack of blinding as unlikely to result in a high risk of detection
bias given the nature of these outcomes
Incomplete outcome data
RCTs
Both trials had high follow-up rates (≤ 10%) and risk of attrition
bias was low.
Cohort
The overall loss to follow-up was 13% and the study used time-
to-event analysis to address this. The authors also report that the
children lost to follow-up did not differ from those remaining
in care in any of the baseline characteristics or timing of ART
initiation and we judged the risk of bias to be low.
Selective reporting
RCTs
We were able to compare the protocol in www.clinicaltrials.gov
with the PREDICT 2012 report and no selective reporting was
noted with a low risk of bias. We were not able to identify the
protocol for Ananworanich 2008 and rated the risk of bias as
unclear.
Cohort
We were not able to compare the protocol with the results and
rated the risk of bias as unclear.
Other potential sources of bias
RCTs
We did not identify other potential sources of bias in either trial.
Cohort
For cohort studies we assessed whether the analysis had ap-
propriately controlled for time-dependent confounding. In the
Yotebieng 2010 cohort the authors made use of inverse proba-
bility-of-treatment and censoring (IPTC) weighting of marginal
structural models, an appropriate statistical analysis to control for
time-dependent confounding, which mimics a randomised trial.
We rated the risk as low.
Effects of interventions
See: Summary of findings for the main comparison
IMMEDIATE initiation of cART compared to DEFERRED
initiation of cART for HIV-positive, treatment-naive children
aged one to 12 years old; Summary of findings 2 Subgroup
analysis: IMMEDIATE initiation of cART compared to
DEFERRED initiation of cART for HIV-positive, treatment-
naive children aged 24 to 59 months (2 to 5 years old)
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We present the outcomes as these were reported in the study re-
ports and include any additional outcomes where these were not
included in our outcomes list in the protocol. As the two trials
were conducted in similar populations we did not consider clin-
ical or methodological heterogeneity as barriers to meta-analysis.
Therefore we have combined the results from both trials in meta-
analyses using the random effects model where possible. Where
indicated, we conducted further sensitivity analyses using differ-
ent analytical models. We report the results from our RevMan cal-
culations and provide narrative results where it was not possible
to extract the data for further analysis e.g. where adjusted analyses
were conducted or where medians were reported.
The authors of both trials provided unpublished age-specific data
for the 24 to 59 month age group for outcomes determined to
be most critical for guideline development, and we present these
results as a post hoc subgroup analysis and report on this in the
text.
For the results from the cohort study, we present the adjusted and
weighted results and not the crude results due to the inherent
confounding present in unadjusted analyses.
Mortality
In the PREDICT 2012 trial, one death was observed in the IM-
MEDIATE group . Due to the low number of events the results
are unlikely to be meaningful (see Analysis 1.1). This death was
in the IMMEDIATE group in the 24 to 59 month age group. See
Analysis 2.1.
In the Yotebieng 2010 cohort study, death was compared in three
different time periods: 1) cART initiation after 15 days following
TB treatment compared with within 15 days; 2) cART initiation
after 30 days (1 month) following TB treatment compared with
within 30 days (1 month); and 3) cART initiation after 60 days
following TB treatment compared within 60 days.
• More than 15 days vs less than 15 days:
◦ The authors calculated a weighted HR accounting for
time-dependent level of immuno-suppression, viral load, weight-
for-age Z score and age at TB treatment initiation. The reported
weighted HR was 0.82 (95% CI: 0.48, 1.41). See Analysis 3.1.
(note that the calculated 95% CI in RevMan differs very slightly
from the 95% CI reported by the authors).
• More than 30 days vs less than 30 days:
◦ The authors calculated a weighted HR of 0.86 (95%
CI: 0.46, 1.60). Weighting accounted for time-dependent level
of immuno-suppression, viral load, weight-for-age Z score and
age at TB treatment initiation. See Analysis 3.1 (note that the
calculated 95% CI in RevMan differs very slightly from the
reported 95% CI).
• More than 60 days vs less than 60 days:
◦ The authors calculated a weighted HR of 1.32 (95%
CI: 0.55, 3.16). Weighting accounted for time-dependent level
of immuno-suppression, viral load, weight-for-age Z score and
age at TB treatment initiation. See Analysis 3.1 (note that the
calculated 95% CI in RevMan differs very slightly from the
reported 95% CI).
From Analysis 3.1 a dose-response gradient can be observed in the
increasing HR values. This indicates that deferring cART initia-
tion to later than 15 days after commencing TB treatment was
protective against death but this effect was reduced at 30 days. De-
ferred initiation became potentially harmful if cART was deferred
beyond 60 days. None of these HR were statistically significantly
different from 1.
NOTE: The denominators in Analysis 3.1 vary with each cut-off
time period due to censoring (the authors provide an example of a
child whose follow-up ended 25 days after TB initiation and prior
to cART who would be classified for the 15 days cut-off but not
for the 30 or 60 day cut-off periods).
Morbidity
AIDS-free survival
In the PREDICT 2012 trial, the authors report an intention-to-
treat analysis of AIDS-free survival rates for all children at week
144 using the Kaplan-Meier product limit method and the IM-
MEDIATE group as the reference group. At week 144 AIDS-free
survival rates in intention to treat analysis were 98.7% (95%CI:
94.7, 99.7%) in the DEFERRED group and 97.9% (95% CI:
93.7, 99.3%) in the IMMEDIATE group (Log rank p=0.6). In
per protocol analysis, AIDS-free survival rates at week 144 were
98.7% (95% CI: 94.7, 99.7%) in the DEFERRED group and
98.6% (95% CI 94.5-99.6%) in the IMMEDIATE group (Log
rank p=0.96).
CDC category C disease
No children in the Ananworanich 2008 trial developed CDC
Category C disease. In the PREDICT 2012 trial three children
in the IMMEDIATE group developed CDC Category C disease
(Pneumocystis jirovecipneumonia (1); Pneumonia/Sepsis leading to
death (1); Disseminated Penicilliosis (1)) and two children devel-
oped Category C disease in the DEFERRED group (Oesaphageal
Candidiasis (1); Extrapulmonary Tuberculosis (1)). We calculated
the relative risk (RR) in RevMan (See Analysis 1.2). The RR was
1.50 (95%CI: 0.25, 8.85; p = 0.65). The authors report CDC cat-
egory C events incidence as 4.9 per 1000 person-years of follow-
up (PYFU) in the DEFERRED group and 7.6 per 1000 PYFU
in the IMMEDIATE group (unadjusted hazard ratio (HR) = 0.7
(95%CI: 0.1, 3.9; p=0.6) and HR adjusted for age and gender =
0.8 (95%CI: 0.1, 4.6; p=0.8).
In the subgroup analysis of the 24 to 59 month age group in the
PREDICT 2012 trial, the RR was 0.96 (95% CI: 0.06, 14.87; p
= 0.98). See Analysis 2.2.
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CDC Category B disease
We combined the data from both trials for children in all age
groups using the random effects model. The RR was 1.42 (95%
CI: 0.14, 14.28; p = 0.77; see Analysis 1.3). We categorised the
pulmonary TB observed in the Ananworanich 2008 trial as CDC
Category B disease. The results show that there was a greater like-
lihood of CDC Category B diseases in the IMMEDIATE group
than in the DEFERRED group but that this was not statistically
significant. However, statistical heterogeneity was present (Chi² =
2.84, df = 1; p = 0.09) with the I² = 65% indicating that there was
substantial heterogeneity not explained by chance.
We conducted a sensitivity analysis and re-analysed the data us-
ing the Peto Odds Ratio (POR) because it is the recommended
approach for uncommon events, particularly when there are trials
with zero events as in the Ananworanich 2008 trial. The POR
was 0.70 (95% CI: 0.39, 1.24; p = 0.22; see Analysis 1.4). Note
that the weighting for Ananworanich 2008 changes from 33.5%
to 7.8% in this analysis. These results indicate that the odds of
developing CDC Category B events was 0.7 times lower in the
IMMEDIATE group than in the DEFERRED group. However,
heterogeneity was present (Chi² = 5.22, df = 1; p = 0.02) with an
I² = 81%.
The high level of heterogeneity would suggest that these results
should not be combined in a meta-analysis, although the second
analysiswhich down-weights theAnanworanich 2008 trial is prob-
ably more appropriate. The authors of PREDICT 2012 report
that CDC class B incidence was 110 (95%CI: 80, 147) events per
1000 PYFU in the DEFERRED group and 88 (95%CI: 61,122)
events per 1000 PYFU in the IMMEDIATE group (incidence rate
ratio (IRR) = 1.25; 95% CI: 0.8, 1.9; p = 0.3). Therefore, early
treatment of 45 children for a year rather than deferring treatment
until CD4 falls to below 15% would prevent 1 CDC category B
event. This result is more consistent with that of Analysis 1.4 (note
the reference or control group is the IMMEDIATE group in the
results reported from the PREDICT 2012 trial, and in Analysis
1.4 the reference group is the DEFERRED group).
In the meta-analysis of the subgroups of 24 to 59 month age
groups, we performed the identical sensitivity analysis to that re-
ported above. The result was similar to that of all age groups (POR
= 0.76; 95% CI: 0.29, 2.02; p = 0.59). See Analysis 2.4.
Pulmonary TB
The incidence of pulmonary TB was low in both trials. We com-
bined the results for children of all age groups in a random effects
meta-analysis (see Analysis 1.5). The risk of developing pulmonary
TB was greater in the IMMEDIATE group than theDEFERRED
group but the difference was not statistically significant (RR =
3.21, 95% CI: 0.52, 19.89; p = 0.21). Heterogeneity was minimal
(Chi² = 0.99, df = 1; p = 0.32); with an I² = 0% indicating no
important statistical heterogeneity.
Given the low number of events we again conducted a sensitivity
analysis using the PetoOddsRatio and found similar results (POR:
3.49, 95% CI: 0.67, 18.13; p = 0.14) with likely unimportant
heterogeneity (Chi² =1.20, df = 1; p =0.27; I² = 17%).The authors
of the Ananworanich 2008 trial report that the four TB events
were not considered to be the result of immune reconstitution
syndromes due to the large gap between ART initiation and TB
diagnosis (median time of 60 weeks with range 48 to 72 weeks).
All four children responded well to anti-TB treatment.
In the meta-analysis of the subgroups of 24 to 59 month age
groups, one case of pulmonary TB was observed in each group
(RR = 1.19; 95% CI: 0.19, 7.27; p = 0.85) with low heterogeneity
(Chi² = 1.36, df = 1; p = 0.24; I² = 26%).
Median time before development of CDC B or C events
Both trials reported on the median time before development of
either CDC B or C events for children of all age groups. In the
Ananworanich 2008 trial, events developed in the IMMEDIATE
group after a median of 60 (IQR: 48 - 72) weeks and no events
developed in theDEFERREDgroup. In the PREDICT 2012 trial,
events developed after a median of 9 (IQR: 4 - 30) weeks since
enrolment in the IMMEDIATE group compared with a median
of 57 (IQR: 34 - 101) weeks in the DEFERRED group.
Virological and immunological response
Virological suppression
1. Proportion of children on cART with HIV-RNA < 50
copies/ml
Both trials provided data on the proportion of children of all
age groups on cART with HIV-RNA < 50 copies/ml, but the
PREDICT 2012 trial restricted analyses to children on first-line
cART for at least 48 weeks whereas this was not the case in the
Ananworanich 2008 trial so we cannot be certain that the time
periods are identical. We combined the data in a random effects
meta-analysis (RR = 0.96; (95% CI: 0.84, 1.09; p = 0.52; see
Analysis 1.7). From these data it is evident that the probability of
a viral load < 50 copies/ml was similar in the IMMEDIATE group
and the DEFERRED group. There was no statistical heterogene-
ity (Chi² = 0.29, df = 1; p = 0.59; I² = 0%).
In the subgroup analysis of the 24 to 59 month age group in the
PREDICT 2012 trial, the results were similar to that for all age
groups (RR = 1.11; 95%CI: 0.86, 1.43; p = 0.43).
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2. Proportion of children on cART with HIV-RNA < 400
copies/ml
The Yotebieng 2010 cohort study assessed virologic suppression
in 70% (324/461) of children who initiated cART and who had at
least one viral loadmeasurement after cART initiation. The results
were analysed in the same three time-periods as for mortality.
• More than 15 days vs less than 15 days:
◦ The authors calculated an adjusted HR which
accounted for baseline differences. The reported adjusted HR
was 0.98 (95% CI: 0.76, 1.26; see Analysis 3.2).
• More than 30 days vs less than 30 days:
◦ The authors calculated a HR adjusted for baseline
differences of 0.95 (95% CI: 0.73, 1.23; see Analysis 3.2).
• More than 60 days vs less than 60 days:
◦ The authors calculated an adjusted HR of 0.84 (95%
CI: 0.61, 1.15; see Analysis 3.2).
As for the analysis of death (see Analysis 3.1) we noted a dose-
response gradient in the hazard ratios for virologic suppression:
children were less likely to achieve virologic suppression for each
increment in deferred time to cART initiation, however, none of
the HRs were statistically significantly different from 1.
Median viral load at study end
The authors of the Ananworanich 2008 trial report on themedian
viral load at the end of the study (median of 134 weeks follow-up)
for children of all age groups. In the IMMEDIATE group, there
was a statistically significantly lower median viral load of 1.7 log10
copies/ml (IQR 1.7 - 2.5) compared with the DEFERRED group
viral load of 3.1 log10 copies/ml (IQR 1.7 - 4.5; p = 0.039). The
median change in viral load at study end was -2.8 log10 copies/ml
(IQR -3.4 to -1.9) in the IMMEDIATE group comparedwith -1.8
log10 copies/ml (IQR: -3.2 to -0.3). The p value for this difference
was p = 0.079.
Median CD4% at study end
For children of all age groups, the authors of Ananworanich 2008
reported that at the end of the study (median of 134 weeks follow-
up), the median CD4% in the IMMEDIATE group was statisti-
cally significantly higher at 31% (IQR: 24 - 39) compared with
the DEFERRED group of median CD4% 23% (IQR: 17 - 31; p
= 0.032). The median CD4% change was 13.5% (IQR: 4 - 18)
in the IMMEDIATE group compared with 3% (IQR: -2 to 13)
in the DEFERRED group (p = 0.012).
Mean CD4% and change in CD4% at week 144
In the PREDICT 2012 trial, the authors report a mean CD4%
at week 144 of 33.2% (SD: 6.4) in the IMMEDIATE group
compared with a mean CD4% of 24.8% (SD: 7.4) in the DE-
FERRED group for children of all age groups. We calculated the
mean difference (see Analysis 1.9) as 8.40% (95% CI: 6.83, 9.97;
p < 0.00001). At the end of the study the mean CD4% in the
IMMEDIATE group was thus higher than in the DEFERRED
group. The authors also conducted a Kaplan-Meier analysis to de-
termine the probability of achieving CD4% ≥30% at week 96.
The probability was 0.83 (95% CI 0.77-0.89) in the IMMEDI-
ATE group and 0.74 (95% CI 0.62-0.84) in the DEFERRED
group (p < 0.001) indicating that the children in the IMMEDI-
ATE group were more likely to achieve CD4%≥30% at week 96.
In the subgroup analysis of the 24 to 59 month age group in the
PREDICT 2012 trial, the mean CD4% at the end of the trial was
5.9% higher in the IMMEDIATE group than in theDEFERRED
group (95%CI: 2.74, 9.06; p = 0.0003; see Analysis 2.7).
Proportion of children with CD4% <15% at study end
In Ananworanich 2008 no children in the IMMEDIATE group
had a CD4% <15% at study end and three children did in the
DEFERREDgroup - all of whomhad less than four week of cART.
In PREDICT 2012, using the Last Observation Carried Forwards
(LOCF) approach, one child in the IMMEDIATE group and
nine children in the DEFERRED group had a CD4% <15% at
study end (unpublished data). The meta-analysis of the combined
data showed that fewer children in the IMMEDIATE group had
CD4% <15% at study end compared with in the DEFERRED
group (RR = 0.11; 95% CI: 0.02, 0.60; p = 0.01). There was no
statistical heterogeneity (see Analysis 1.10). In the 24 to 59 month
age group, the proportion of children with CD4% <15% in the
IMMEDIATE group was lower than that in the DEFERRED
group but the results were less precise and no longer statistically
significant (RR = 0.40; 95% CI: 0.06, 2.52; p = 0.33, see Analysis
2.8).
Growth parameters
Weight
In the PREDICT 2012 trial, for all age groups, the mean weight
gain per year was 2.2kg (SD: 1.1) in the IMMEDIATE group
and 2.1kg (SD: 1.2) in the DEFERRED group, for a mean differ-
ence of 0.1kg (95% CI: -0.16, 0.36; p = 0.45; see Analysis 1.11).
Median weight-for-age z scores at study end were available for all
children in both trials. In the Ananworanich 2008 trial, the score
in the IMMEDIATE group was -1.1 (IQR: -1.5 to -0.8) and in
the DEFERRED group the score was -1.0 (IQR: -1.7 to 0.2). In
the PREDICT 2012 trial, the score was -1.27 (IQR: -1.78 to -
0.39) in the IMMEDIATE group and -1.40 (IQR: -1.99 to -0.89)
in the DEFERRED group. These scores indicate that growth was
compromised in both groups in both trials (see Analysis 1.12).
The change in median weight-for-age z score was calculated in
PREDICT 2012. In the IMMEDIATE group, the change in me-
dian score was 0.26 (IQR: -2.00 to -0.75) which was a greater gain
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in weight than the median change in score of 0.04 (IQR: -0.28
to 0.34) in the DEFERRED group (p = 0.02 for difference). In
a multivariate model, the authors found that the effect of group
allocation remained significant (p = 0.01) after adjusting for base-
line CD4% (< 20% and ≥ 20%), age (< 5 years and ≥ 5 years),
haemoglobin level, and HIV RNA level. In the analysis of the 24
to 59 month age group in the PREDICT 2012 trial, weight gain
was similar in the IMMEDIATE and DEFERRED groups, with
a mean difference of - 0.03kg (95% CI: -0.25, 0.19; p = 0.79, see
Analysis 2.9).
Height
In the PREDICT 2012 trial, for all ages, the mean height gain
per year was 5.4cm (SD: 1.4) in the IMMEDIATE group and
4.9cm (SD: 1.2) in the DEFERRED group, for a mean difference
of 0.50cm (95% CI: 0.20, 0.80; p = 0.0009); see Analysis 1.13).
Median height-for-age z scores at study end were available in both
trials. In the Ananworanich 2008 trial, the score in the IMMEDI-
ATE group was -1.4 (IQR: -2.0 to -0.8) and in the DEFERRED
group the score was -0.8 (IQR: -1.3 to -0.4). In the PREDICT
2012 trial, the score was -1.50 (IQR: -2.35 to -0.54) in the IM-
MEDIATE group and -1.73 (IQR: -2.42 to -0.95) in the DE-
FERRED group. These scores indicate that height was compro-
mised in both groups in both trials (see Analysis 1.14). The change
in median height-for-age z score was calculated in the PREDICT
2012 trial. In the IMMEDIATE group, the change in median
score was 0.25 (IQR: -0.21 to -0.69) in the IMMEDIATE group
and the median change in score was -0.02 (IQR: -0.40 to 0.34) in
the DEFERRED group (p = 0.004 for difference). The children
in the IMMEDIATE group thus gained more height than those in
theDEFERRED group. In an adjusted analysis, the authors found
that the effect of group allocation remained significant (p = 0.002)
after adjusting for baseline CD4% (< 20% and ≥ 20%), age (< 5
years and ≥ 5 years), haemoglobin level, and HIV RNA level. In
the analysis of the 24 to 59 month age group in PREDICT 2012,
mean height gain was slightly greater in the IMMEDIATE group
compared to the DEFERRED group, with a mean difference of
0.3cm (95%CI: -0.28, 0.88; p = 0.31; see Analysis 2.10).
Neurological parameters
In the PREDICT 2012 trial, the neurodevelopment sub-study
was phased in after the main study had started and baseline Beery
Visual Motor Integration assessment was only performed in 71
children. The mean baseline scores for children of all age groups
in the IMMEDIATE and DEFERRED groups were 81.5 (SD:
17.2) and 87.1 (SD: 14.4) respectively. There was no statistically
significant difference between the groups at study end (week 144).
The mean difference was -1.40 (95%CI: -4.70, 1.90; p = 0.41; see
Analysis 1.15). The authors report that for the 71 childrenwhohad
a baseline assessment, the mean difference in Beery standard score
change from baseline from week 0 to 144 between IMMEDIATE
and DEFERRED arms was -4·37 (-12·00 to 3·26; p =0·26). In
the subgroup analysis, the Beery Visual Motor Integration score
was available for 42 and 40 of the children aged 24 to 59 months
in the IMMEDIATE and DEFERRED group respectively. Again,
there was no statistically significant difference between the groups
at study end. The mean difference was 2.3 (95% CI: -4.37, 8.97;
p = 0.50; see Analysis 2.11).
Adverse events
The Ananworanich 2008 trial reported on the proportion of chil-
dren of all age groups with adverse events, but did not provide
data on the severity of the events. All children in the DEFERRED
group and 92% of those in the IMMEDIATE group experienced
an adverse event (RR = 0.92; 95% CI: 0.80, 1.07; p = 0.29). Both
trials reported on the proportion of children of all age groups with
adverse events related to cART. Children in the IMMEDIATE
group were more likely to develop cART-related adverse events
than those in the DEFERRED group but this was not statistically
significant (RR = 1.87; 95% CI: 0.77, 4.51; p = 0.17) and there
was little statistical heterogeneity (Chi² = 0.96, df = 1; p = 0.33;
I² = 0%). The proportion of children in the 24 to 59 month age
group in the PREDICT 2012 trial with ART-related Grade 3 or
4 events was lower in the IMMEDIATE group than in the DE-
FERRED group (RR = 0.48; 95%CI: 0.04, 5.11; p = 0.54; see
Analysis 2.12).
GRADE ASSESSMENTS
GRADE assessments were conducted for all outcomes where data
was available to enter into GRADEPro. For the Summary of Find-
ings tables we selected seven outcomes per comparison based on
what is most important to patients.
Overall, the quality of evidence observed in the two trials was
low or very low. For evidence for initiation of cART in all age
groups, we down-graded the evidence for indirectness (as the age
group was not specific to the population group of interest) and
for serious or very serious imprecision. The PREDICT 2012 trial
was well-conducted with the sample size planned to be powered
for the primary outcome of AIDS-free survival; however, due to
the low number of events and slow disease progression, the study
was ultimately under-powered to adequately assess this outcome.
Note that we did not create a Summary of Findings Table for the
outcome of AIDS-free survival. For all other outcomes, the sample
size was considered small and for most outcomes the event rate
was extremely small, leading to imprecision in the results. This
remained when combined with the data from the Ananworanich
2008 trial as the trial added only 43 children to the total. See
Summary of findings for the main comparison.
For the post hoc subgroup analysis of ages 24 to 59 months, we
did not downgrade for indirectness as the population was specific
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to the question of this review. However, as this was a post hoc
analysis, the risk of selection bias resulted in downgrading for risk
of bias. We continued to downgrade for very serious imprecision
due to the small sample size, the low event rate andwide confidence
intervals. See Summary of findings 2.
For the evidence arising from the observational study (Yotebieng
2010), the quality of evidence was rated as very low for all out-
comes. We downgraded for risk of bias due to a residual risk of
selection bias: we cannot be certain that the IPTC weighting of
marginal structural models removed all bias. As the study included
children aged one to 15 years we downgraded for indirectness.
Due to the low number of events, we downgraded for serious im-
precision.
Using the GRADE approach, we are very uncertain of the effect
estimates overall.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
SUBGROUP ANALYSIS: IMMEDIATE initiation of cART compared to DEFERRED initiation of cART in HIV-positive, treatment-naive children aged 24 to 59 months (2 to 5 years old)
Patient or population: HIV-positive, treatment-naive children aged 24 to 59 months (2 to 5 years old)
Settings: Thailand and Cambodia
Intervention: SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control SUBGROUP ANALYSIS:
IMMEDIATE versus DE-
FERRED initiation of ART
24 to 59 months (RCT)
Death 0 per 1000 0 per 1000
(0 to 0)
RR 2.88
(0.12 to 68.88)
122
(2 studies)
⊕©©©
very low1,2
CDC Category C disease
(number of children)
16 per 1000 15 per 1000
(1 to 236)
RR 0.96
(0.06 to 14.87)
122
(2 studies)
⊕©©©
very low1,2
CDC Category B disease
(numbers of children)
Peto Odds Ratio
239 per 1000 167 per 1000
(70 to 355)
OR 0.64
(0.24 to 1.75)
94
(1 study)
⊕©©©
very low3,4
Proportion of children on
ART with HIV-RNA <50
copies/ml
789 per 1000 876 per 1000
(679 to 1000)
RR 1.11
(0.86 to 1.43)
67
(1 study)
⊕©©©
very low5,6
Mean weight gain per
year in kg
The mean weight gain per
year in kg in the interven-
tion groups was
0.03 lower
(0.25 lower to 0.19
higher)
94
(1 study)
⊕©©©
very low3,7
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Mean height gain per
year in cm
The mean height gain per
year in cm in the interven-
tion groups was
0.3 higher
(0.28 lower to 0.88
higher)
94
(1 study)
⊕©©©
very low3,7
Mean standardized
score on Beery VMI at
144 weeks
The mean standardized
score on Beery VMI at
144 weeks in the inter-
vention groups was
2.3 higher
(4.37 lower to 8.97
higher)
82
(1 study)
⊕©©©
very low3,7
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 This is a subgroup analysis within each of the Ananworanich 2009 and PREDICT 2012 trials. Randomisation was not conducted within
the sub-group. For Ananworanich 2008, the proportion of children aged 24 to 59 months in the IMMEDIATE group was 46% (11/24)
and in the DEFERRED group it was 89% (17/19). This differential could introduce selection bias.
2 The sample size of the two subgroups of age-specific data for 24 to 59 months is 122 and the event rate is very small. The confidence
interval is very large.
3 Randomisation was not conducted within the sub-group. In the PREDICT trial, the proportion of the overall sample in the subgroup
in the IMMEDIATE group was 32% (48/150) and in the DEFERRED group it was 31% (46/150). Although this is balanced, we cannot
exclude the possibility of selection bias as this analysis was conducted post hoc.
4 The sample size of the subgroup of age-specific data for 24 to 59 months in the PREDICT 2012 trial is 94 and the event rate is very
small. The confidence interval is large.
5 Randomisation was not conducted within the sub-group. In the PREDICT trial, the proportion of the overall sample in the subgroup
in the IMMEDIATE group was 32% (48/150) and in the DEFERRED group it was 31% (46/150). In this comparison (children on ART
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with HIV-RNA <copies/ml) only those children on ART in the DEFERRED group (19/150) were included so the proportions are very
imbalanced.
6 The sample size of the two subgroups of age-specific data for 24 to 59 months is small (N = 67). Imprecision is likely to be present.
7 The sample size is very small. In the GRADE system, imprecision is likely to be present when continuous outcomes are compared in
samples less than 400.
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D I S C U S S I O N
Summary of main results
Our review identified limited evidence from two small randomised
controlled trials evaluating the effects of initiating cART in chil-
dren aged one to 12 years immediately at CD4% between 15 and
25%, compared with deferring cART until pre-defined immuno-
logical and clinical thresholds. No differences in outcomes were
noted between the randomised groups.
We identified a single cohort study which compared delaying
cART in HIV-infected children co-infected with TB with initiat-
ing cART soon after commencing TB treatment. Delaying cART
initiation to later than 15 days after commencing TB treatment
was protective against death but this effect was reduced at 30 days,
and potentially harmful if cART was deferred beyond 60 days.
None of the studies exclusively included children within the spe-
cific focus age of two to five years.
Overall completeness and applicability of
evidence
The trials included in this review did not evaluate the effects of
immediate or deferred initiation of cART in children aged two to
five years, but in the broader age group of one to 12 years. Al-
though wewere able to obtain age-specific data from the two trials,
the evidence generated from these post hoc sub-group analyses is
less robust given that randomisation did not take place within the
age-specific sub-group. Stronger evidence would be gained from
replicating trials within the specific age group, but it is unlikely
that new trials will assess this in future. Antiretroviral treatment
has been indicated for all HIV-positive infants and children less
than two years of age since 2010 (WHO 2010b). As cART be-
comes increasingly available across the world, identification and
recruitment into trials of children aged two or more may no longer
be feasible.
The evidence generated from the two trials and the single included
cohort study arise from resource-constrained settings affected by
theHIV/AIDS epidemic (Thailand, Cambodia and South Africa).
The participants in the trials are therefore likely to be representative
of HIV-infected children living in poverty. However, the children
and their carers were from urban settings and in this respect the
results may not be generalizable to those children and their carers
living in impoverished rural areas.
Quality of the evidence
The quality of the methodological conduct for the larger
PREDICT 2012 trial was judged to be high and the risk of bias
was likely to be low to moderate for both trials overall. However,
when using the GRADE approach to assess the overall quality of
the evidence generated in the review, the quality of the evidence
was rated as low or very low. This was due to the indirectness of the
included population and the marked imprecision present in the
results. Imprecision was driven largely by the small sample size and
low event rates. The sample size of the PREDICT 2012 trial was
powered for the primary outcome of AIDS-free survival; however,
due to the low number of events and slow disease progression, the
study was ultimately under-powered to adequately assess this and
this reduced the quality of the evidence.
In the Yotebieng 2010 cohort study, close attention was paid to
confounding and the authors addressed this via weighted adjusted
analyses which included adjusting for time-dependent level of im-
muno-suppression, viral load, weight-for-age Z score and age at
TB treatment initiation. Despite this, the quality of evidence gen-
erated by a single cohort study was appraised in GRADE as pro-
viding very low evidence due to selection bias (lack of randomisa-
tion), indirectness and imprecision.
Potential biases in the review process
Possible selection biases in the review process were minimised
by using a comprehensive search strategy to identify studies and,
wherever possible, independently selecting and appraising the
studies. In addition to searching journal and conference electronic
databases, we conducted hand-searching of several important con-
ference abstract books, including the International Workshop on
HIV Pediatrics and recent relevant conferences not yet included in
the electronic databases. We contacted several authors of confer-
ence abstracts to confirm whether the data in their abstract cor-
responded to subsequent journal articles or to assess whether the
reported data was eligible for inclusion in this review. it is unlikely
that important trials have been missed given the high-profile na-
ture of the topic and the close partnership established with agen-
cies and organizations working in this area.
Data extraction was done independently by one author and then
checked by a second author. Ideally all data extraction should be
conducted independently by two authors; however, this was not
feasible given the time constraints of the rapid review process. The
results were presented at a WHOGuidelines Committee Meeting
inDecember 2012 providing a further check of the data by experts
and investigators familiar with the data, thereby reducing any po-
tential measurement bias introduced by a single author conduct-
ing data extraction.
We conducted several sensitivity analyses using different statisti-
cal models and estimates of effect. This was especially important
to do for several of the analyses which were limited by small de-
nominators and few events (Higgins 2009). Conducting sensitiv-
ity analyses allowed us to interrogate the data closely and consider
the robustness of the findings.
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Agreements and disagreements with other
studies or reviews
We were unable to identify any other studies or reviews address-
ing the question of when to start cART in children aged 24 to
59 months. Lewis et al monitored 127 children enrolled in the
Paediatric European Network for the Treatment of AIDS 5 and
found that initiation of cART at higher CD4 counts may improve
long term immune reconstitution and may potentially reduce the
so-called ’non-AIDS’ morbidity developed as a result of immune
activation without causing harm or significantly increasing drug-
related toxicity (Lewis 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is lack of sufficient evidence from clinical trials to assess
whether immediate versus deferred initiation of cART in children
aged between 2 and 5 years provides clinical and immunological
benefits.
While individual level benefits are still unclear, from a program-
matic point of view starting cART in all children below 5 years of
age may facilitate a more rapid scale-up of paediatric treatment in
resource-limited settings where coverage remains low. Removing
the CD4 barrier to treatment initiation for children less than five
years is likely to result in prompter initiation of cART for those eli-
gible children whose treatment is delayed while they wait for CD4
tests and results. In these settings it will nevertheless be critical to
prioritise cART to those children with a higher risk of mortality
where early ART initiation has proven mortality benefit, such as
infants less than one year of age and those with advanced clinical
and immunological disease.
Based on the evidence in this review, in settings with wide access to
CD4 monitoring, good cART coverage and adequate programme
retention, CD4-guided initiation of cART should not be viewed as
sub-optimal standard of care. Adequate pre-cART clinical follow-
up should be strengthened to ensure prompt recognition of disease
progression as soon as this may occur.
Implications for research
Large randomised trials assessing morbidity and mortality as well
as clinical and immunological outcomes with adequate follow-up
are warranted to provide the evidence base for effective decision
making on when to start cART in children aged 24 to 59 months
in resource-limited settings.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ananworanich 2008
Methods STUDY TYPE:
• Randomised controlled trial
COUNTRY:
• Thailand
SETTING:
• Research clinical sites: The HIV Netherlands Australia Thailand Research
Collaboration/Chulalongkorn University in Bangkok and the Khon Kaen University in
Northeast Thailand
DURATION OF RECRUITMENT:
• Dec 2001 - Mar 2003 (Bangkok); Oct 2002 - Mar 2003 (Khon Kaen)
DURATION OF TRIAL:
• 3 years and 3 months. Completed March 2005
FOLLOW-UP:
• Length of follow-up was 108 weeks.
• Children were followed monthly for the first three months and then every three
months.
• At baseline, CD4 was tested by flow cytometry and CBC and alanine transferase
(ALT) were tested.
• At every visit, CD4, Complete Blood Count and ALT were tested.
• At every 24 week visit, viral load (Roche Amplicor Ultrasensitive assay), fasting
lipids and glucose were tested.
• Median duration of follow-up from randomization: 134 (IQR: 123 - 154) weeks
This trial was a pilot study was conducted to explore the feasibility and HIV disease
outcome of the immediate versus deferred strategy as ground work for the PREDICT
trial (PREDICT 2012).
Participants INCLUSION CRITERIA:
• Children aged one to 12 years old, with HIV infection, with CDC clinical stage A
or B and who had never received ART other than zidovudine as part of PMTCT.
EXCLUSION CRITERIA:
• Children younger than one year.
• Children with CDC C or CD4 < 15%
• Children without symptoms or with normal CD4 (> 25%)
Number of participants randomised: 43
• Median age at randomization: IMMEDIATE group: 5.2 (IQR: 2.4 - 8.0) years;
DEFERRED group: 4.4 (IQR: 2.7 - 5.8) years
• Gender distribution (Male: Female) (n, %): IMMEDIATE group:10:14 (42: 58);
DEFERRED group: 7: 12 (37: 63)
• Median weight for age z-scores (WAZ) (IQR): IMMEDIATE group: -1.0 (-1.5 -
0.4); DEFERRED group: -0.1 (-1.5 - 0.3)
• Median height for age z-scores (WAZ) (IQR): IMMEDIATE group: -1.7 (-2.0 -
0.9); DEFERRED group: -0.8 (-1.7 - 0.1)
• Median percent CD4 count (%; IQR): IMMEDIATE group: 19 (16 - 22);
DEFERRED group: 20 (17 - 22)
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Ananworanich 2008 (Continued)
• Median CD4 count (cells/mm3; IQR): IMMEDIATE group: 649 (509 - 834);
DEFERRED group: 615 (544 - 818)
All characteristics and baseline data did not differ between the two groups except median
triglyceride at 48 weeks. This was statistically significantly higher in the DEFERRED
group (98; IQR: 70 - 148) compared with the IMMEDIATE group (69: IQR: 54 - 88)
(p = 0.016)
Interventions INTERVENTION: IMMEDIATE GROUP
• Participants were started on ART immediately at study entry.
CONTROL: DEFERRED GROUP
• Participants were started on ART when CD4 fell to < 15% in those with baseline
CD4 20 - 24% or CD4 dropped by 25% in those with baseline CD4 15 - 19%. A
repeat confirmatory CD4 was done immediately if CD4 fell below ART initiation
threshold.
ART comprised standard doses of generic individual zidovudine, lamivudine and nevi-
rapine according to the Thai Government Pharmaceutical Organization guidelines
COMPLIANCE:
No formal means of assessing compliance is reported.
CO-INTERVENTIONS:
Cotrimoxazole was started immediately with the first decrease of CD4 below 15% and
was continued for at least three months until two consecutive CD4 were above 15%
Outcomes PRIMARY OUTCOMES:
• Recruitment rate
• Adherence to randomized group
• Retention in the study
SECONDARY OUTCOMES:
• Proportion (%) children with CDC C or with CD4 < 15%
• Growth
• Median CD4%
• Median Viral load
• ART savings (reduced time on ART)
• ART-related Adverse Events (measured using the 1994 Adult and Pediatric
Grading Tables of the Division of AIDS, NIH (DAIDS 1994)
Notes ETHICS
Institutional Review Board at Chulalongkorn and Khon Kaen Universities
INFORMED CONSENT:
All caregivers gave signed informed consent.
FUNDING
Not specifically reported. The Thai Government Pharmaceutical Organization provided
anti-retrovirals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not reported
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Ananworanich 2008 (Continued)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk This was an open-label trial so personnel
and caregiverswere not blinded, potentially
introducing performance bias
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk In the IMMEDIATE group, attrition was
1/24 (4.2%) and in the DEFERRED
group, attrition was 2/19 (10.5%). We
judged this to be low risk
Selective reporting (reporting bias) Low risk We were not able to identify a registered
protocol for the trial to compare registered
and reported outcomes. However, given
that the trial was designed as a feasibility
study with recruitment rate, adherence and
retention as primary outcomes rather than
measures of efficacy, we judged the risk of
selective reporting to be low
Control of time-dependent confounding
COHORT ONLY
Low risk Not applicable due to the nature of ran-
domisation which eliminates the need to
control for confounding
Other bias Unclear risk The trial was conducted to ascertain the
feasibility of the larger PREDICT 2012
trial and was intentionally not powered to
evaluate efficacy. We did not identify other
sources of bias
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PREDICT 2012
Methods STUDY TYPE:
• Randomised controlled trial
COUNTRY:
• Thailand
• Cambodia
SETTING:
• Nine tertiary referral hospitals and research sites of the Comprehensive
International Program for Research in IADS (CIPRA) - Thailand and Cambodia
Network
DURATION OF RECRUITMENT:
• Mar 2006 - Sep 2008
DURATION OF TRIAL:
• 5 years and 3 months. Trial completed in May 2011
FOLLOW-UP:
• Length of follow-up was 144 weeks.
• Children in the IMMEDIATE group were followed at weeks 2, 4, 8, 12 and then
every 12 weeks thereafter; children in the DEFERRED group were followed at weeks
8, 12 and every 12 weeks thereafter
• At baseline, all children were evaluated clinically, and complete blood count,
CD4% and count, serum electrolytes and alanine aminotransferase (ALT) were
performed
• At every follow-up visit, clinical evaluation was done including an assessment for
toxicity or HIV-related events
• At every 12 week visit, complete blood count, CD4% and count, serum
electrolytes and Alanine Transferase (ALT) were performed
• At every 24 week visit, plasma HIV RNA (viral load) and Beery Visual Motor
Integration (VMI) tests were conducted
• 96% of children completed 144 weeks of follow-up.
Participants INCLUSION CRITERIA:
• Children aged one to 12 years old, with HIV infection (defined as positive HIV
DNA PCR or RNA PCR twice among children between 12 and 18 months, or with
positive HIV antibody test among children aged > 18 months)
• CD4% 15 - 24%
• No history of AIDS illness (CDC C events)
• Never received ART other than for prevention of MTCT
EXCLUSION CRITERIA:
• Children younger than one year
• Active AIDS-defining illness
• Use of immunosuppressive drugs
• Use of immuno-modulators within 30 days prior to study entry
• Abnormal laboratory results:
◦ Absolute neutrophil count < 750 cells/mm3
◦ Haemoglobin < 7.5 g/dL
◦ Platelet count < 50,000/mm3
◦ ALT > 4 times upper limit of normal (ULN)
Number of participants randomised: 300
Baseline data:
• Median age at randomization (IQR): IMMEDIATE group: 6.4 (IQR: 3.6 - 8.0)
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PREDICT 2012 (Continued)
years; DEFERRED group: 6.5 (IQR: 4.2 - 8.7) years
• Number and % in age groups (n (%)):
◦ 1 - 3 years: IMMEDIATE group: 45 (30); DEFERRED group: 33 (22)
◦ 4 - 6 years: IMMEDIATE group: 43 (29); DEFERRED group: 50 (33)
◦ 7 - 9 years: IMMEDIATE group: 44 (30); DEFERRED group: 49 (33)
◦ 10 - 12 years: IMMEDIATE group: 17 (11); DEFERRED group: 18 (12)
• Gender distribution (Male: Female) (n, %): IMMEDIATE group:77: 72 (48; 52);
DEFERRED group: 54:96 (36: 64)
• Median weight for age z-scores (WAZ) (IQR): IMMEDIATE group: -1.3 (-2.0 to
-0.8); DEFERRED group: -1.3 (-2.0 to -0.8)
• Median height for age z-scores (WAZ) (IQR): IMMEDIATE group: -1.6 (-2.5 to
-0.8); DEFERRED group: -1.7 (-2.6 to -0.9)
• Median percent CD4 count (%; IQR): IMMEDIATE group: 19 (16 - 22);
DEFERRED group: 20 (17 - 23)
• Median CD4 count (cells/mm3; IQR): IMMEDIATE group: 620 (425 - 851);
DEFERRED group: 619 (466 - 847)
Baseline characteristics were similar between the two groups except for gender. There was
a significantly greater proportion of females in the deferred arm (p value not reported)
Interventions INTERVENTION: IMMEDIATE GROUP
• Participants were started on ART immediately at study entry
CONTROL: DEFERRED GROUP
• Participants were started on ART during the trial if
◦ Development of CDC category C events OR
◦ Confirmed CD4% decline to < 15% prior to December 2008 for all
children OR
◦ Confirmed CD4% decline to < 20% in children aged 1 to 3 years from
December 2008*
*The change in the immunologic criteria was due to a change in World Health Orga-
nization and national treatment guidelines. Recruitment was completed in September
2008 prior to implementing the change
First-line ART comprised:
• Zidovudine, lamivudine and nevirapine
• A protease inhibitor (lopinavir/ritonavir or nelfinavir) was substituted for
nevirapine in children with prior exposure to nevirapine (nelfinavir was not used after
September 2007)
• Abacavir was substituted for zidovudine in cases of grade 3 or 4 hematologic
toxicity
• Efavirenz or a protease inhibitor was substituted for nevirapine in children with
nevirapine- hypersensitivity depending on the severity
• Children also requiring anti-tuberculosis treatment received zidovudine,
lamivudine and abacavir
Second-line ART:
• ART treatment failure was defined as HIV RNA >1000 copies/ml after ≥6
months of treatment
• ART selection was based on genotypic resistance testing.
COMPLIANCE:
Adherence questionnaires and pill counts were used to assess adherence. Good adherence
(defined as average adherence by pill count of > 95% while receiving study drug) was
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PREDICT 2012 (Continued)
reported in 88% of the IMMEDIATE and 90% of the DEFERRED group
CO-INTERVENTIONS:
Cotrimoxazole was started immediately with the first decrease of CD4 below 15% and
was continued for at least six months until two consecutive CD4 were above 15%
Outcomes PRIMARY OUTCOMES:
• CDC Category C event-free (AIDS-fee) survival at week 144
SECONDARY OUTCOMES:
• CDC Category B events
• Beery VM standard score
• Hospitalization rates
• CD4% changes
• Growth changes
• Cumulative proportion of children with virologic failure
• ART-related Adverse Events (measured using the 2004 Adult and Pediatric
Grading Tables of the Division of AIDS, NIH.
Notes ETHICS
Institutional Review Board permission obtained at all sites.
INFORMED CONSENT:
All caregivers gave written informed consent.
FUNDING
Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, Na-
tional Institute of Child Health and Human Development (NICHD) and National In-
stitute of Mental Health (NIMH), US National Institutes of Health (NIH)
Antiretroviral drugs were provided by ViiV Healthcare/GlaxoSmithKline (zidovudine,
lamivudine and abacavir), Boehringer-Ingelheim (nevirapine),Merck (efavirenz), Abbott
(lopinavir/ritonavir) and Roche (nelfinavir)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation pro-
gram using SAS 9.1. The randomisation
employed minimization by research site
and history of nevirapine exposure
Allocation concealment (selection bias) Low risk The process was done centrally at a trial co-
ordinating centre in Bangkok and assign-
ment was communicated to the site inves-
tigator via fax
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Caregivers and personnel were not blinded
as the study was open-label. This may in-
troduce performance bias
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PREDICT 2012 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk An independent committee blinded to as-
signment, CD4 and ART status, reviewed
outcomes of CDC category B and C end-
points and hospitalizations. Other out-
comes may have been susceptible to detec-
tion bias but we judged this to be of low
risk
Incomplete outcome data (attrition bias)
All outcomes
Low risk In the IMMEDIATE group, 7/150 (4.
6%) were lost-to-follow-up and in the DE-
FERRED group, 3/150 (2%) were lost-to-
follow-up. This represents a low attrition
rate
Selective reporting (reporting bias) Low risk We compared the trial report with the entry
for NCT00234091 on www.clinicaltrials.
gov. There was no selective reporting
Control of time-dependent confounding
COHORT ONLY
Low risk Not applicable due to the nature of ran-
domisation which eliminates the need to
control for confounding
Other bias Low risk The trial was funded by government orga-
nizations. The drugswere supplied by phar-
maceutical companies which had no role
in the study design, analysis or manuscript
preparation. The trial was not stopped
early. For these reasons we judged the risk
of bias to be low for other forms of bias
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Yotebieng 2010
Methods STUDY TYPE:
• Observational cohort study using prospectively routinely collected data
COUNTRY:
• South Africa
SETTING:
• Harriet Shezi Children’s Clinic, an outpatient paediatric clinic at Chris Hani
Baragwanath Hospital in Soweto (tertiary facility)
DURATION OF RECRUITMENT:
• Apr 2004 - Mar 2008
DURATION OF TRIAL:
• 4 years. Completed on 31 March 2008 or at last visit before 31 March 2008 by
administrative censoring
FOLLOW-UP:
• Median length of follow-up 9.6 months (IQR: 1.9 - 23.1 months)
• Children were followed after one month, then at three months and then every
three months or as clinically indicated
• At baseline, laboratory investigations (CD4 cell count and viral load) were
conducted
• At every 6 monthly visit, CD4 and viral load were conducted on when indicated
Participants INCLUSION CRITERIA:
• Children (age defined as younger than 15 years old and assumed to be excluding
infants (less than one years old)), with HIV infection, with tuberculosis (TB) infection
diagnosed by clinical grounds including:
◦ Failure to thrive
◦ Prolonged (more than 2 weeks) cough
◦ Suspicious chest radiograph
◦ With or without positive contact history
◦ Bacteriological confirmation was attempted in older children who could
produce sputum samples
• TB treatment must have been initiated prior to ART initiation
EXCLUSION CRITERIA:
• Children already on TB treatment at first visit in the clinic
Number of participants eligible for inclusion: 573
• Median age of all children at baseline (age in years; IQR): 3.5 years (1.4 - 6.8)
• Gender distribution (Male: Female) (n, %): Not reported
• Median weight for age z-scores of all children at baseline (WAZ) (IQR): -2.3 (-3.6
to -1.3)
• Median height for age z-scores of all children at baseline (WAZ) (IQR): Not
reported
• Median percent CD4 count of all children at baseline (%; IQR): 11.9% (6.6 - 18.
3)
• Median viral load for all children at baseline (log copies/ml; IQR): 5.2 (4.5 - 5.9)
Characteristics and baseline data were compared between those who initiated ART and
those who did not initiate ART and between those who initiated ARTwithin one month
from enrolment and those who initiated ART equal to or greater than one month from
enrolment. As the comparison this review is focused on is timing on ART initiation, the
baseline results are presented for those who initiated ART within one month (n = 288)
and greater or equal to one month (n = 206) below:
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Yotebieng 2010 (Continued)
• Median age of children at TB treatment initiation (age in years; IQR): ART
INITIATED < 1 MONTH: 3.5 years (1.4 - 7.1); ART INITIATED ≥ 1 MONTH: 3.
5 (1.4 - 6.7)
• Median weight for age z-scores of children: (WAZ) (IQR): ART INITIATED < 1
MONTH: -2.71 (-4.11 to 1.60); ART INITIATED ≥ 1 MONTH: -1.92 (-2.92 to -0.
83)
• Median percent CD4 count of children (%; IQR): ART INITIATED < 1
MONTH 8.0 (4.6 - 13.6): ART INITIATED ≥ 1 MONTH: 15.0 (9.8-21.2)
• Median CD4 cell count of children (count/microL; IQR): ART INITIATED < 1
MONTH 273 (98 - 604): ART INITIATED ≥ 1 MONTH: 533 (238 - 868)
• Median viral load for children (log copies/ml; IQR): ART INITIATED < 1
MONTH: 5.3 (4.6 - 6.0); ART INITIATED ≥ 1 MONTH: 5.2 (4.5 - 5.8)
• Median time from TB to ART initiation (days; IQR): ART INITIATED < 1
MONTH: 4 (0 - 14); ART INITIATED ≥ 1 MONTH: 59 (42 - 130)
The baseline difference between the groups was statistically significant for CD4 cell
count, CD4 cell percentage, WAZ, and time from TB to ART initiation
The authors report that the distribution of baseline characteristics was similar to that of
the above for 15 and 60 day cut-offs. The actual data is not reported
Interventions INTERVENTION: ART INITIATED < 1 MONTH
ART was initiated in children within one month of enrolment
CONTROL: ART INITIATED ≥ 1 MONTH
ART was initiated in children after one month or more of enrolment
The authors also consider the data in 15-day and 60-day cut-offs
First-line ART regimen at the time, according to South African National Guidlines.
comprised stavudine, lamivudine, and ritonavir-boosted lopinavir for children three years
or younger; or stavudine, lamivudine and efavirenz for those over three years and over
10kg of weight. Double doses of ritonavir were given during anti-TB treatment
CO-INTERVENTIONS:
All children were receiving TB treatment which comprised a combination of rifampicin,
isoniazid, and pyrazinamide for the initial two months followed by rifampicin and iso-
niazid for the remaining four months
Outcomes PRIMARY OUTCOMES:
• Survival (time from TB treatment initiation to death)
• Time to viral suppression (time from ART initiation to date of first viral load
measure below 400 HIV RNA copies/ml)
Notes ETHICS
Not reported. Routine data collection
INFORMED CONSENT:
Not reported.
FUNDING
US National Institutes of Health (NIH) Fogarty grant: DHHS/NIH/FIC 5 D43
TW01039-08 AIDS International Training and Research Program at the University of
North Carolina (UNC) at Chapel Hill. Additional support from the UNC Center of
Global Initiative and the American International Health Alliance
Antiretroviral drugs were provided by ViiV Healthcare/GlaxoSmithKline (zidovudine,
lamivudine and abacavir), Boehringer-Ingelheim (nevirapine),Merck (efavirenz), Abbott
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Yotebieng 2010 (Continued)
(lopinavir/ritonavir) and Roche (nelfinavir)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk The groups were not randomised as this
was a cohort study.
Allocation concealment (selection bias) High risk The groups were not randomised as this
was a cohort study.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk As the personnel determined when to ini-
tiate ART, blinding was not possible and
performance bias may be present
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The authors do not report if the assessment
was blinded. However as the outcomes are
death and viral load lack of blinding is un-
likely to be a major source of bias
Incomplete outcome data (attrition bias)
All outcomes
Low risk The overall loss to follow-up was 13% (75/
573) overall with 38 lost prior to ART ini-
tiation and 37 while on ART. The authors
report that those children lost to follow-up
did not differ to those in care in any of the
baseline characteristics or timing of ART
initiation
Selective reporting (reporting bias) Unclear risk No protocol was obtained for this study
and there is no report of ethical clearance.
As it is based on analysis of routinely col-
lected data there is a risk of selective report-
ing of those outcomes which were found to
be significant or noteworthy in preference
over other outcomes. However, given that
the outcomes of death and viral suppres-
sion are of primary interest to the research
question, we did not rate the risk as high
but as unclear
Control of time-dependent confounding
COHORT ONLY
Low risk The authors made use of inverse proba-
bility-of-treatment and censoring (IPTC)
weighting of marginal structural models,
an appropriate statistical analysis to control
for time-dependent confounding
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Yotebieng 2010 (Continued)
Other bias Low risk The authors state that the funding sources
had no role in the design and conduct of
this study
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Edmonds 2009 The analysis estimated the effect of ART versus no ART on the incidence of TB (rather than the effect of starting
ART earlier or later)
Edmonds 2011 The analysis estimated the effect of ART versus no ART on the incidence of TB (rather than the effect of starting
ART earlier or later)
Munyagwa 2012 This analysis compared ART versus no ART and was not appropriately adjusted for (it did not consider time-
dependent confounding)
Musoke 2010 This study analyzed growth trajectories and immunological and virological response of children starting ART.
There were no morbidity/mortality endpoints and no appropriate comparisons of starting early versus starting
late
Patel 2008 a The analysis did not include mortality and morbidity data and estimated the effect of ART versus no ART (rather
than the effect of starting earlier or later.)
Patel 2008 b In this study the analysis estimated the effect of ART versus no ART (rather than the effect of starting ART earlier
or later)
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D A T A A N D A N A L Y S E S
Comparison 1. IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 343 Risk Ratio (M-H, Random, 95% CI) 3.0 [0.12, 73.06]
2 CDC Category C disease
(number of children)
2 343 Risk Ratio (M-H, Random, 95% CI) 1.5 [0.25, 8.85]
3 CDC Category B disease
(numbers of children) Relative
Risk
2 343 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.14, 14.28]
4 CDC Category B disease
(numbers of children) Peto
Odds Ratio
2 343 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.70 [0.39, 1.24]
5 Pulmonary TB (clinically
diagnosed)
2 343 Risk Ratio (M-H, Fixed, 95% CI) 3.21 [0.52, 19.89]
6Median time before development
of CDC B or C event
Other data No numeric data
7 Proportion of children on ART
with HIV-RNA < 50 copies/ml
2 238 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.84, 1.09]
8 Median CD4% at study end Other data No numeric data
9 Mean CD4% at week 144 1 300 Mean Difference (IV, Random, 95% CI) 8.40 [6.83, 9.97]
10 Proportion of children with
CD4% < 15% at study end
2 343 Risk Ratio (M-H, Random, 95% CI) 0.11 [0.02, 0.60]
11 Mean weight gain per year in
kg
1 299 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.16, 0.36]
12 Median weight-for-age Z score
at study end (134 - 144 weeks)
Other data No numeric data
13 Mean height gain per year in
cm
1 300 Mean Difference (IV, Fixed, 95% CI) 0.5 [0.20, 0.80]
14 Median height-for-age Z score
at study end (134 - 144 weeks)
Other data No numeric data
15 Mean standardized score on
Beery VMI at 144 weeks
1 272 Mean Difference (IV, Fixed, 95% CI) -1.40 [-4.70, 1.90]
16 Proportion of children with
adverse events
1 43 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.80, 1.07]
17 Proportion of children with
ART-related adverse events
2 343 Risk Ratio (M-H, Random, 95% CI) 1.87 [0.77, 4.51]
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Comparison 2. SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months
(RCT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 2 122 Risk Ratio (M-H, Random, 95% CI) 2.88 [0.12, 68.88]
2 CDC Category C disease
(number of children)
2 122 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.06, 14.87]
3 CDC Category B disease
(numbers of children) Relative
Risk
2 122 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.24, 3.73]
4 CDC Category B disease
(numbers of children) Peto
Odds Ratio
2 122 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.76 [0.29, 2.02]
5 Pulmonary TB (clinically
diagnosed)
2 122 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.19, 7.27]
6 Proportion of children on ART
with HIV-RNA < 50 copies/ml
1 67 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.86, 1.43]
7 Mean CD4% at week 144 1 94 Mean Difference (IV, Random, 95% CI) 5.90 [2.74, 9.06]
8 Proportion of children with
CD4% < 15% at study end
2 122 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.06, 2.52]
9 Mean weight gain per year in kg 1 94 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.25, 0.19]
10 Mean height gain per year in
cm
1 94 Mean Difference (IV, Fixed, 95% CI) 0.30 [-0.28, 0.88]
11 Mean standardized score on
Beery VMI at 144 weeks
1 82 Mean Difference (IV, Fixed, 95% CI) 2.30 [-4.37, 8.97]
12 Proportion of children with
ART-related Grade 3 or 4
adverse events
1 94 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.04, 5.11]
Comparison 3. ADJUSTED/WEIGHTED EARLY vs DEFERRED initiation of ART in children with TB and
HIV
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death 1 Hazard Ratio (Fixed, 95% CI) Subtotals only
1.1 > 15 DAYS vs =< 15
DAYS
1 501 Hazard Ratio (Fixed, 95% CI) 0.82 [0.52, 1.31]
1.2 > 30 DAYS vs =< 30
DAYS
1 494 Hazard Ratio (Fixed, 95% CI) 0.86 [0.49, 1.52]
1.3 > 60 DAYS vs =< 60
DAYS
1 489 Hazard Ratio (Fixed, 95% CI) 1.32 [0.36, 4.87]
2 Virologic suppression 1 Hazard Ratio (Fixed, 95% CI) Subtotals only
2.1 > 15 DAYS vs =< 15
DAYS
1 324 Hazard Ratio (Fixed, 95% CI) 0.98 [0.76, 1.26]
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2.2 > 30 DAYS vs =< 30
DAYS
1 324 Hazard Ratio (Fixed, 95% CI) 0.95 [0.74, 1.22]
2.3 > 60 DAYS vs =< 60
DAYS
1 324 Hazard Ratio (Fixed, 95% CI) 0.84 [0.64, 1.10]
Analysis 1.1. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 1
Death.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 1 Death
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 0/24 0/19 0.0 [ 0.0, 0.0 ]
PREDICT 2012 1/150 0/150 3.00 [ 0.12, 73.06 ]
Total (95% CI) 174 169 3.00 [ 0.12, 73.06 ]
Total events: 1 (IMMEDIATE), 0 (DEFERRED)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMMEDIATE Favours DEFERRED
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Analysis 1.2. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 2
CDC Category C disease (number of children).
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 2 CDC Category C disease (number of children)
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 0/24 0/19 0.0 [ 0.0, 0.0 ]
PREDICT 2012 3/150 2/150 1.50 [ 0.25, 8.85 ]
Total (95% CI) 174 169 1.50 [ 0.25, 8.85 ]
Total events: 3 (IMMEDIATE), 2 (DEFERRED)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMMEDIATE Favours DEFERRED
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Analysis 1.3. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 3
CDC Category B disease (numbers of children) Relative Risk.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 3 CDC Category B disease (numbers of children) Relative Risk
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 4/24 0/19 33.5 % 7.20 [ 0.41, 125.97 ]
PREDICT 2012 20/150 32/150 66.5 % 0.63 [ 0.38, 1.04 ]
Total (95% CI) 174 169 100.0 % 1.42 [ 0.14, 14.28 ]
Total events: 24 (IMMEDIATE), 32 (DEFERRED)
Heterogeneity: Tau2 = 2.02; Chi2 = 2.84, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMMEDIATE Favours DEFERRED
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Analysis 1.4. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 4
CDC Category B disease (numbers of children) Peto Odds Ratio.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 4 CDC Category B disease (numbers of children) Peto Odds Ratio
Study or subgroup IMMEDIATE DEFERRED
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Ananworanich 2008 4/24 0/19 7.8 % 6.89 [ 0.89, 53.37 ]
PREDICT 2012 20/150 32/150 92.2 % 0.57 [ 0.32, 1.04 ]
Total (95% CI) 174 169 100.0 % 0.70 [ 0.39, 1.24 ]
Total events: 24 (IMMEDIATE), 32 (DEFERRED)
Heterogeneity: Chi2 = 5.22, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 1.24 (P = 0.22)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMMEDIATE Favours DEFERRED
Analysis 1.5. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 5
Pulmonary TB (clinically diagnosed).
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 5 Pulmonary TB (clinically diagnosed)
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ananworanich 2008 4/24 0/19 35.7 % 7.20 [ 0.41, 125.97 ]
PREDICT 2012 1/150 1/150 64.3 % 1.00 [ 0.06, 15.84 ]
Total (95% CI) 174 169 100.0 % 3.21 [ 0.52, 19.89 ]
Total events: 5 (IMMEDIATE), 1 (DEFERRED)
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours IMMEDIATE Favours DEFERRED
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Analysis 1.6. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 6
Median time before development of CDC B or C event.
Median time before development of CDC B or C event
Study IMMEDIATE (time on ART before events) DEFERRED (time from enrolment to events)
Ananworanich 2008 60 (IQR: 48 - 72) weeks Nil
PREDICT 2012 9 (IQR: 4 - 30) weeks 57 (IQR: 34 - 101) weeks
Analysis 1.7. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 7
Proportion of children on ART with HIV-RNA < 50 copies/ml.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 7 Proportion of children on ART with HIV-RNA < 50 copies/ml
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 16/24 6/10 5.0 % 1.11 [ 0.62, 1.98 ]
PREDICT 2012 121/149 47/55 95.0 % 0.95 [ 0.83, 1.09 ]
Total (95% CI) 173 65 100.0 % 0.96 [ 0.84, 1.09 ]
Total events: 137 (IMMEDIATE), 53 (DEFERRED)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours DEFERRED Favours IMMEDIATE
Analysis 1.8. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 8
Median CD4% at study end.
Median CD4% at study end
Study IMMEDIATE DEFERRED P value
46Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Median CD4% at study end (Continued)
Ananworanich 2008 Median (IQR): 31 (24 - 39) Median (IQR): 23 (17 - 31) 0.032
Analysis 1.9. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 9
Mean CD4% at week 144.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 9 Mean CD4% at week 144
Study or subgroup IMMEDIATE DEFERRED
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDICT 2012 150 33.2 (6.4) 150 24.8 (7.4) 100.0 % 8.40 [ 6.83, 9.97 ]
Total (95% CI) 150 150 100.0 % 8.40 [ 6.83, 9.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 10.52 (P < 0.00001)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 1.10. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 10
Proportion of children with CD4% < 15% at study end.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 10 Proportion of children with CD4% < 15% at study end
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 0/24 3/19 33.3 % 0.11 [ 0.01, 2.09 ]
PREDICT 2012 1/150 9/150 66.7 % 0.11 [ 0.01, 0.87 ]
Total (95% CI) 174 169 100.0 % 0.11 [ 0.02, 0.60 ]
Total events: 1 (IMMEDIATE), 12 (DEFERRED)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 2.56 (P = 0.011)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.11. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 11
Mean weight gain per year in kg.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 11 Mean weight gain per year in kg
Study or subgroup IMMEDIATE DEFERRED
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
PREDICT 2012 149 2.2 (1.1) 150 2.1 (1.2) 100.0 % 0.10 [ -0.16, 0.36 ]
Total (95% CI) 149 150 100.0 % 0.10 [ -0.16, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 12
Median weight-for-age Z score at study end (134 - 144 weeks).
Median weight-for-age Z score at study end (134 - 144 weeks)
Study IMMEDIATE DEFERRED
Ananworanich 2008 -1.1 (IQR: -1.5 to -0.8) -1.0 (IQR: -1.7 to 0.2)
PREDICT 2012 -1.27 (IQR: -1.78 to -.0.39) -1.40 (IQR: -1.99 to -0.89)
Analysis 1.13. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 13
Mean height gain per year in cm.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 13 Mean height gain per year in cm
Study or subgroup IMMEDIATE DEFERRED
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
PREDICT 2012 150 5.4 (1.4) 150 4.9 (1.2) 100.0 % 0.50 [ 0.20, 0.80 ]
Total (95% CI) 150 150 100.0 % 0.50 [ 0.20, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.32 (P = 0.00090)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 14
Median height-for-age Z score at study end (134 - 144 weeks).
Median height-for-age Z score at study end (134 - 144 weeks)
Study IMMEDIATE DEFERRED
Ananworanich 2008 -1.4 (IQR: -2.0 to -0.8) -0.8 (IQR: -1.3 to -0.4)
PREDICT 2012 -1.50 (IQR: -2.35 to -.0.54) -1.73 (IQR: -2.42 to -0.95)
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Analysis 1.15. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 15
Mean standardized score on Beery VMI at 144 weeks.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 15 Mean standardized score on Beery VMI at 144 weeks
Study or subgroup IMMEDIATE DEFERRED
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
PREDICT 2012 132 85.2 (13.8) 140 86.6 (14) 100.0 % -1.40 [ -4.70, 1.90 ]
Total (95% CI) 132 140 100.0 % -1.40 [ -4.70, 1.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
Test for subgroup differences: Not applicable
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Analysis 1.16. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 16
Proportion of children with adverse events.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 16 Proportion of children with adverse events
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 22/24 19/19 100.0 % 0.92 [ 0.80, 1.07 ]
Total (95% CI) 24 19 100.0 % 0.92 [ 0.80, 1.07 ]
Total events: 22 (IMMEDIATE), 19 (DEFERRED)
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
Test for subgroup differences: Not applicable
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Analysis 1.17. Comparison 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT), Outcome 17
Proportion of children with ART-related adverse events.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 1 IMMEDIATE versus DEFERRED initiation of ART all ages (RCT)
Outcome: 17 Proportion of children with ART-related adverse events
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 7/24 4/19 67.8 % 1.39 [ 0.47, 4.04 ]
PREDICT 2012 7/150 2/150 32.2 % 3.50 [ 0.74, 16.57 ]
Total (95% CI) 174 169 100.0 % 1.87 [ 0.77, 4.51 ]
Total events: 14 (IMMEDIATE), 6 (DEFERRED)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 1 Death.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 1 Death
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 0/11 0/17 0.0 [ 0.0, 0.0 ]
PREDICT 2012 1/48 0/46 2.88 [ 0.12, 68.88 ]
Total (95% CI) 59 63 2.88 [ 0.12, 68.88 ]
Total events: 1 (IMMEDIATE), 0 (DEFERRED)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 2 CDC Category C disease (number of children).
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 2 CDC Category C disease (number of children)
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 0/11 0/17 0.0 [ 0.0, 0.0 ]
PREDICT 2012 1/48 1/46 0.96 [ 0.06, 14.87 ]
Total (95% CI) 59 63 0.96 [ 0.06, 14.87 ]
Total events: 1 (IMMEDIATE), 1 (DEFERRED)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 3 CDC Category B disease (numbers of children) Relative Risk.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 3 CDC Category B disease (numbers of children) Relative Risk
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 1/11 0/17 16.6 % 4.50 [ 0.20, 101.52 ]
PREDICT 2012 8/48 11/46 83.4 % 0.70 [ 0.31, 1.58 ]
Total (95% CI) 59 63 100.0 % 0.95 [ 0.24, 3.73 ]
Total events: 9 (IMMEDIATE), 11 (DEFERRED)
Heterogeneity: Tau2 = 0.41; Chi2 = 1.30, df = 1 (P = 0.25); I2 =23%
Test for overall effect: Z = 0.07 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 4 CDC Category B disease (numbers of children) Peto Odds Ratio.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 4 CDC Category B disease (numbers of children) Peto Odds Ratio
Study or subgroup IMMEDIATE DEFERRED
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Ananworanich 2008 1/11 0/17 5.9 % 12.75 [ 0.23, 705.29 ]
PREDICT 2012 8/48 11/46 94.1 % 0.64 [ 0.24, 1.75 ]
Total (95% CI) 59 63 100.0 % 0.76 [ 0.29, 2.02 ]
Total events: 9 (IMMEDIATE), 11 (DEFERRED)
Heterogeneity: Chi2 = 2.01, df = 1 (P = 0.16); I2 =50%
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 5 Pulmonary TB (clinically diagnosed).
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 5 Pulmonary TB (clinically diagnosed)
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Ananworanich 2008 1/11 0/17 20.7 % 4.50 [ 0.20, 101.52 ]
PREDICT 2012 0/48 1/46 79.3 % 0.32 [ 0.01, 7.65 ]
Total (95% CI) 59 63 100.0 % 1.19 [ 0.19, 7.27 ]
Total events: 1 (IMMEDIATE), 1 (DEFERRED)
Heterogeneity: Chi2 = 1.36, df = 1 (P = 0.24); I2 =26%
Test for overall effect: Z = 0.18 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 2.6. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 6 Proportion of children on ART with HIV-RNA < 50 copies/ml.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 6 Proportion of children on ART with HIV-RNA < 50 copies/ml
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
PREDICT 2012 42/48 15/19 100.0 % 1.11 [ 0.86, 1.43 ]
Total (95% CI) 48 19 100.0 % 1.11 [ 0.86, 1.43 ]
Total events: 42 (IMMEDIATE), 15 (DEFERRED)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 7 Mean CD4% at week 144.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 7 Mean CD4% at week 144
Study or subgroup IMMEDIATE DEFERRED
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
PREDICT 2012 48 32.8 (8.03) 46 26.9 (7.59) 100.0 % 5.90 [ 2.74, 9.06 ]
Total (95% CI) 48 46 100.0 % 5.90 [ 2.74, 9.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.66 (P = 0.00025)
Test for subgroup differences: Not applicable
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Analysis 2.8. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 8 Proportion of children with CD4% < 15% at study end.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 8 Proportion of children with CD4% < 15% at study end
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Ananworanich 2008 0/11 2/17 39.2 % 0.30 [ 0.02, 5.72 ]
PREDICT 2012 1/48 2/46 60.8 % 0.48 [ 0.04, 5.11 ]
Total (95% CI) 59 63 100.0 % 0.40 [ 0.06, 2.52 ]
Total events: 1 (IMMEDIATE), 4 (DEFERRED)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 2.9. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 9 Mean weight gain per year in kg.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 9 Mean weight gain per year in kg
Study or subgroup IMMEDIATE DEFERRED
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
PREDICT 2012 48 1.44 (0.6) 46 1.47 (0.5) 100.0 % -0.03 [ -0.25, 0.19 ]
Total (95% CI) 48 46 100.0 % -0.03 [ -0.25, 0.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
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Analysis 2.10. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 10 Mean height gain per year in cm.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 10 Mean height gain per year in cm
Study or subgroup IMMEDIATE DEFERRED
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
PREDICT 2012 48 5.4 (1.7) 46 5.1 (1.1) 100.0 % 0.30 [ -0.28, 0.88 ]
Total (95% CI) 48 46 100.0 % 0.30 [ -0.28, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 11 Mean standardized score on Beery VMI at 144 weeks.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 11 Mean standardized score on Beery VMI at 144 weeks
Study or subgroup IMMEDIATE DEFERRED
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
PREDICT 2012 42 86.5 (13.8) 40 84.2 (16.8) 100.0 % 2.30 [ -4.37, 8.97 ]
Total (95% CI) 42 40 100.0 % 2.30 [ -4.37, 8.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24
to 59 months (RCT), Outcome 12 Proportion of children with ART-related Grade 3 or 4 adverse events.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 2 SUBGROUP ANALYSIS: IMMEDIATE versus DEFERRED initiation of ART 24 to 59 months (RCT)
Outcome: 12 Proportion of children with ART-related Grade 3 or 4 adverse events
Study or subgroup IMMEDIATE DEFERRED Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
PREDICT 2012 1/48 2/46 100.0 % 0.48 [ 0.04, 5.11 ]
Total (95% CI) 48 46 100.0 % 0.48 [ 0.04, 5.11 ]
Total events: 1 (IMMEDIATE), 2 (DEFERRED)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 ADJUSTED/WEIGHTED EARLY vs DEFERRED initiation of ART in children
with TB and HIV, Outcome 1 Death.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 3 ADJUSTED/WEIGHTED EARLY vs DEFERRED initiation of ART in children with TB and HIV
Outcome: 1 Death
Study or subgroup
DEFERRED
INITIA-
TION EARLY INITIATION log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 > 15 DAYS vs =< 15 DAYS
Yotebieng 2010 275 -0.19845094 (0.237245) 226 100.0 % 0.82 [ 0.52, 1.31 ]
Subtotal (95% CI) 100.0 % 0.82 [ 0.52, 1.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2 > 30 DAYS vs =< 30 DAYS
Yotebieng 2010 206 -0.15082289 (0.290816) 288 100.0 % 0.86 [ 0.49, 1.52 ]
Subtotal (95% CI) 100.0 % 0.86 [ 0.49, 1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
3 > 60 DAYS vs =< 60 DAYS
Yotebieng 2010 111 378 0.27763174 (0.665816) 100.0 % 1.32 [ 0.36, 4.87 ]
Subtotal (95% CI) 100.0 % 1.32 [ 0.36, 4.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.68)
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Analysis 3.2. Comparison 3 ADJUSTED/WEIGHTED EARLY vs DEFERRED initiation of ART in children
with TB and HIV, Outcome 2 Virologic suppression.
Review: Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old
Comparison: 3 ADJUSTED/WEIGHTED EARLY vs DEFERRED initiation of ART in children with TB and HIV
Outcome: 2 Virologic suppression
Study or subgroup
DEFERRED
INITIA-
TION EARLY INITIATION log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 > 15 DAYS vs =< 15 DAYS
Yotebieng 2010 172 -0.02020271 (0.127551) 152 100.0 % 0.98 [ 0.76, 1.26 ]
Subtotal (95% CI) 100.0 % 0.98 [ 0.76, 1.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
2 > 30 DAYS vs =< 30 DAYS
Yotebieng 2010 127 -0.05129329 (0.127551) 197 100.0 % 0.95 [ 0.74, 1.22 ]
Subtotal (95% CI) 100.0 % 0.95 [ 0.74, 1.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
3 > 60 DAYS vs =< 60 DAYS
Yotebieng 2010 59 -0.17435339 (0.137755) 265 100.0 % 0.84 [ 0.64, 1.10 ]
Subtotal (95% CI) 100.0 % 0.84 [ 0.64, 1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
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A P P E N D I C E S
Appendix 1. Medline search strategy for RCT records
Search Query Items found
#9 Search (#6 AND #7) AND (“1980/01/01”[Date - Publica-
tion] : “2012/06/27”[Date - Publication])
914
#8 Search #6 AND #7 914
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(Continued)
#7 Search infant[mh] OR infant*[tiab] OR toddler*[tiab] OR
child[mh] OR child*[tiab] OR preschool*[tiab] OR pre-
school*[tiab] OR schoolchild*[tiab] OR paediatric*[tiab]
OR pediatric*[tiab]
2158897
#6 Search #3 AND #4 AND #5 6912
#5 Search optimal time[tiab] OR optimal timing[tiab] OR op-
timum time[tiab] OR optimum timing[tiab] OR time fac-
tors[mh] OR time factor[tiab] OR time factors[tiab] OR ini-
tiate[tiab] OR initiating[tiab] OR initiation[tiab] OR “when
to start”[tiab] OR early treatment[tiab] OR deferred treat-
ment[tiab] OR earlier treatment[tiab] OR best time[tiab]
OR best timing[tiab] OR (start*[tiab] AND therapy[tiab])
1155983
#4 Search (randomized controlled trial [pt] OR controlled clin-
ical trial [pt] OR randomized [tiab] OR placebo [tiab] OR
drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR
groups [tiab]) NOT (animals [mh] NOT humans [mh])
2566592
#3 Search #1 AND #2 76113
#2 Search antiretroviral therapy, highly active[MeSH] OR anti-
retroviral agents[MeSH]ORantiviral agents[MeSH:NoExp]
OR ((anti[tiab]) AND (hiv[tiab])) OR antiretroviral*[tiab]
OR ((anti[tiab]) AND (retroviral*[tiab])) ORHAART[tiab]
OR ((anti[tiab]) AND (acquired immunodeficiency[tiab]))
OR ((anti[tiab]) AND (acquired immuno-deficiency[tiab]))
OR ((anti[tiab]) AND (acquired immune-deficiency[tiab]))
OR ((anti[tiab]) AND (acquired immun*[tiab]) AND (de-
ficiency[tiab]))
120941
#1 Search HIV Infections[MeSH] OR HIV[MeSH] OR
hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab]
OR hiv2[tiab] OR hiv infect*[tiab] OR human im-
munodeficiency virus[tiab] OR human immunedeficiency
virus[tiab] OR human immuno-deficiency virus[tiab] OR
human immune-deficiency virus[tiab] OR ((human im-
mun*[tiab]) AND (deficiency virus[tiab])) OR acquired im-
munodeficiency syndrome[tiab] OR acquired immunede-
ficiency syndrome[tiab] OR acquired immuno-deficiency
syndrome[tiab] OR acquired immune-deficiency syn-
drome[tiab] OR ((acquired immun*[tiab]) AND (deficiency
syndrome[tiab])) OR “sexually transmitted diseases, Vi-
ral”[MeSH:NoExp]
283522
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Appendix 2. EmBase search strategy for RCT records
No. Query Results
#14 #11 AND #12 AND [embase]/lim AND [1980-2012]/py 616
#13 #11 AND #12 696
#12 ’infant’ OR ’infant’/de OR infant OR infant*:ab,ti OR ’tod-
dler’ OR ’toddler’/deOR toddlerOR toddler*:ab,tiOR ’child’
OR ’child’/deOR childOR child*:ab,ti OR ’preschool child’/
deOR ’preschool child’ OR preschool*:ab,ti OR pre+school*:
ab,ti OR ’school child’/de OR ’school child’ OR schoolchild*:
ab,ti OR paediatric:ab,ti OR pediatric*:ab,ti
3159338
#11 #3 AND #9 AND #10 4287
#10 ’optimal time’:ab,ti OR ’optimal timing’:ab,ti OR ’optimum
time’:ab,ti OR ’optimum timing’:ab,ti OR ’time’/de OR time
OR ’time factor’:ab,ti OR ’time factors’:ab,ti OR initiate:ab,ti
OR initiating:ab,ti OR initiation:ab,ti OR ’when to start’:ab,
ti OR ’early treatment’:ab,ti OR ’deferred treatment’:ab,ti OR
’earlier treatment’:ab,ti OR ’best time’:ab,ti OR ’best timing’:
ab,ti OR (start* NEXT/3 therapy):ab,ti
2769213
#9 #4 NOT #8 1579892
#8 #5 NOT #7 1971197
#7 #5 AND #6 16771510
#6 ’human’/de OR ’human’ 17150693
#5 ’animal’/deOR ’animal’ OR ’nonhuman’/de OR ’nonhuman’
OR ’animal experiment’/de OR ’animal experiment’
18742707
#4 ’randomized controlled trial’/de OR ’randomized controlled
trial’ OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR fac-
torial*:ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volun-
teer*:ab,ti OR ’crossover procedure’/de OR ’crossover proce-
dure’ OR ’double-blind procedure’/de OR ’double-blind pro-
cedure’ OR ’single-blind procedure’/de OR ’single-blind pro-
cedure’ OR (doubl* NEAR/3 blind*):ab,ti OR (singl*:ab,ti
AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:ab,ti
OR (cross NEXT/1 over*):ab,ti
1654771
#3 #1 AND #2 126378
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(Continued)
#2 ’human immunodeficiency virus vaccine’/de OR ’human im-
munodeficiency virus vaccine’OR ’human immunodeficiency
virus vaccine’:ab,ti OR ’anti human immunedeficiency’:ab,
ti OR ’anti human immunodeficiency’:ab,ti OR ’anti hu-
man immuno-deficiency’:ab,ti OR ’anti human immune-de-
ficiency’:ab,tiOR ’anti acquired immune-deficiency’:ab,tiOR
’anti acquired immunedeficiency’:ab,ti OR ’anti acquired im-
munodeficiency’:ab,ti OR ’anti acquired immuno-deficiency’:
ab,ti OR ’anti hiv’:ab,ti OR antiretrovir*:ab,ti OR ’anti retro-
viral’:ab,ti OR ’anti retrovirals’:ab,ti OR ’anti retrovirus’:ab,
ti OR haart:ab,ti OR ’aids vaccine’:ab,ti OR ’aids vaccines’:
ab,ti OR ’anti human immunodeficiency virus agent’/de OR
’anti human immunodeficiency virus agent’ OR ’antiretro-
virus agent’/deOR ’antiretrovirus agent’ OR ’highly active an-
tiretroviral therapy’/de OR ’highly active antiretroviral ther-
apy’ OR ’highly active antiretroviral therapy’:ab,ti
147069
#1 ’human immunodeficiency virus infection’/exp OR ’human
immunodeficiency virus infection’/de OR ’human immun-
odeficiency virus infection’ OR ’human immunodeficiency
virus’/exp OR ’human immunodeficiency virus’/de OR ’hu-
man immunodeficiency virus’ OR ’human immunodeficiency
virus:ab,ti’ OR hiv:ab,ti OR ’hiv-1’:ab,ti OR ’hiv-2’:ab,ti OR
’human immunodeficiency virus’:ab,tiOR ’human immuned-
eficiency virus’:ab,tiOR ’human immune-deficiency virus’:ab,
ti OR ’human immuno-deficiency virus’:ab,ti OR ’acquired
immunodeficiency syndrome’:ab,ti OR ’acquired immuno-
deficiency syndrome’:ab,ti OR ’acquired immune-deficiency
syndrome’:ab,ti OR ’acquired immunedeficiency syndrome’:
ab,ti
380494
Appendix 3. CENTRAL search strategy for RCT records
ID Search Hits
#1 MeSH descriptor HIV Infections explode all trees 6664 MeSH descriptor HIV Infections explode all trees 6664
#2 MeSH descriptor HIV explode all trees 2235
#3 hiv OR hiv-1* OR hiv-2* OR hiv1 OR hiv2 OR HIV
INFECT* OR HUMAN IMMUNODEFICIENCY
VIRUS OR HUMAN IMMUNEDEFICIENCY VIRUS
OR HUMAN IMMUNE-DEFICIENCY VIRUS
OR HUMAN IMMUNO-DEFICIENCY VIRUS
OR HUMAN IMMUN* DEFICIENCY VIRUS OR
10868
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ACQUIRED IMMUNODEFICIENCY SYNDROME
OR ACQUIRED IMMUNEDEFICIENCY SYNDROME
OR ACQUIRED IMMUNO-DEFICIENCY
SYNDROME OR ACQUIRED IMMUNE-
DEFICIENCY SYNDROME OR ACQUIRED IMMUN*
DEFICIENCY SYNDROME
#4 MeSH descriptor Lymphoma, AIDS-Related, this term only 21
#5 MeSH descriptor Sexually Transmitted Diseases, Viral, this
term only
22
#6 (#1 OR #2 OR #3 OR #4 OR #5) 10945
#7 MeSH descriptor Antiretroviral Therapy, Highly Active,
this term only
827
#8 MeSH descriptor Anti-HIV Agents explode all trees 2222
#9 MeSH descriptor Antiviral Agents, this term only 2886
#10 MeSH descriptor AIDS Vaccines, this term only 284
#11 ANTI HIV OR ANTIRETROVIRAL* OR ANTI
RETROVIRAL* OR AIDS VACCIN*
4961
#12 (#7 OR #8 OR #9 OR #10 OR #11) 7832
#13 (#6 AND #12) 5338
#14 MeSH descriptor Time Factors, this term only 44585
#15 time factor:ti,ab OR time factors:ti,ab OR optimal
time:ti,ab OR optimal timing:ti,ab OR initiate:ti,ab OR
initiating:ti,ab OR initiation:ti,ab OR “when to start”:ti,ab
OR early treatment:ti,ab OR deferred treatment:ti,ab OR
earlier treatment:ti,ab OR best time:ti,ab OR best
timing:ti,ab OR (start* NEXT/3 therapy):ti,ab
51057
#16 (#14 OR #15) 88247
#17 infant:ti,ab,kw OR toddler:ti,ab,kw OR child:ti,ab,kw OR
preschool*:ti,ab,kw OR pre school:ti,ab,kw OR
schoolchild*:ti,ab,kw OR paediatric*:ti,ab,kw OR
pediatric*:ti,ab,kw
77426
#18 (#13 AND #16 AND #17) 238
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#19 (#13 AND #16 AND #17), from 1980 to 2012 127
Appendix 4. Medline search strategy for cohort records (excluding RCT records)
Search Query Items found
#13 Search (#10 NOT #11) AND (“1980/01/01”[Date - Publi-
cation] : “2012/09/11”[Date - Publication])
130
#12 Search #10 NOT #11 130
#11 Search (randomized controlled trial [pt] OR controlled clin-
ical trial [pt] OR randomized [tiab] OR placebo [tiab] OR
drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR
groups [tiab]) NOT (animals [mh] NOT humans [mh])
2600091
#10 Search #6 AND #9 584
#9 Search #7 OR #8 1482738
#8 Search (follow up[tiab] OR prospective[tiab] OR longitudi-
nal[tiab]) AND (study[tiab] OR studies[tiab])
577814
#7 Search cohort studies[mh] OR cohort[tiab] 1263329
#6 Search #3 AND #4 AND #5 1271
#5 Search infant[mh] OR infant*[tiab] OR toddler*[tiab] OR
child[mh] OR child*[tiab] OR preschool*[tiab] OR pre-
school*[tiab] OR schoolchild*[tiab] OR paediatric*[tiab]
OR pediatric*[tiab]
2177077
#4 Search optimal time[tiab] OR optimal timing[tiab] OR op-
timum time[tiab] OR optimum timing[tiab] OR time fac-
tors[mh] OR time factor[tiab] OR time factors[tiab] OR ini-
tiate[tiab] OR initiating[tiab] OR initiation[tiab] OR “when
to start”[tiab] OR early treatment[tiab] OR deferred treat-
ment[tiab]ORearlier treatment[tiab]ORbest time[tiab]OR
best timing[tiab] OR (start*[tiab] AND therapy[tiab])
1167527
#3 Search #1 AND #2 77367
#2 Search antiretroviral therapy, highly active[MeSH] OR anti-
retroviral agents[MeSH] OR antiviral agents[MeSH:NoExp]
OR ((anti[tiab]) AND (hiv[tiab])) OR antiretroviral*[tiab]
122889
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OR ((anti[tiab]) AND (retroviral*[tiab])) ORHAART[tiab]
OR ((anti[tiab]) AND (acquired immunodeficiency[tiab]))
OR ((anti[tiab]) AND (acquired immuno-deficiency[tiab]))
OR ((anti[tiab]) AND (acquired immune-deficiency[tiab]))
OR ((anti[tiab]) AND (acquired immun*[tiab]) AND (defi-
ciency[tiab]))
#1 Search HIV Infections[MeSH] OR HIV[MeSH] OR
hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab]
OR hiv2[tiab] OR hiv infect*[tiab] OR human im-
munodeficiency virus[tiab] OR human immunedeficiency
virus[tiab] OR human immuno-deficiency virus[tiab] OR
human immune-deficiency virus[tiab] OR ((human im-
mun*[tiab]) AND (deficiency virus[tiab])) OR acquired im-
munodeficiency syndrome[tiab] OR acquired immunede-
ficiency syndrome[tiab] OR acquired immuno-deficiency
syndrome[tiab] OR acquired immune-deficiency syn-
drome[tiab] OR ((acquired immun*[tiab]) AND (deficiency
syndrome[tiab])) OR “sexually transmitted diseases, Vi-
ral”[MeSH:NoExp]
286626
Appendix 5. EmBase search strategy for cohort records (excluding RCT records)
No. Query Results
#15 #8 NOT #14 AND [embase]/lim AND [1-1-1980]/sd NOT
[11-9-2012]/sd
950
#14 #9 NOT #13 1612308
#13 #10 NOT #12 2100850
#12 #10 AND #11 17006261
#11 ’human’/de OR ’human’ 17384855
#10 ’animal’/deOR ’animal’ OR ’nonhuman’/de OR ’nonhuman’
OR ’animal experiment’/de OR ’animal experiment’
19107111
#9 ’randomized controlled trial’/de OR ’randomized controlled
trial’ OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR fac-
torial*:ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volun-
teer*:ab,ti OR ’crossover procedure’/de OR ’crossover proce-
dure’ OR ’double-blind procedure’/de OR ’double-blind pro-
cedure’ OR ’single-blind procedure’/de OR ’single-blind pro-
cedure’ OR (doubl* NEAR/3 blind*):ab,ti OR (singl*:ab,ti
1689960
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AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:ab,ti
OR (cross NEXT/1 over*):ab,ti
#8 #6 AND #7 1316
#7 #3 AND #4 AND #5 3218
#6 ’cohort analysis’/exp OR ’cohort analysis’ OR ’longitudinal
study’/exp OR ’longitudinal study’ OR ’prospective study’/
expOR ’prospective study’ OR ’follow up’/expOR ’follow up’
OR cohort*:ab,tiOR ’longitudinal studies’:ab,tiOR ’prospec-
tive studies’:ab,ti
1911861
#5 ’infant’/de OR infant*:ab,ti OR ’toddler’/de OR toddler*:ab,
ti OR ’child’/de OR child*:ab,ti OR ’preschool child’/de OR
’preschool child’ OR preschool*:ab,ti OR pre+school*:ab,ti
OR ’school child’/deOR schoolchild*:ab,ti OR paediatric:ab,
ti OR pediatric*:ab,ti
2459580
#4 ’optimal time’:ab,ti OR ’optimal timing’:ab,ti OR ’optimum
time’:ab,ti OR ’optimum timing’:ab,ti OR ’time’/de OR time
OR ’time factor’:ab,ti OR ’time factors’:ab,ti OR initiate:ab,ti
OR initiating:ab,ti OR initiation:ab,ti OR ’when to start’:ab,
ti OR ’early treatment’:ab,ti OR ’deferred treatment’:ab,ti OR
’earlier treatment’:ab,ti OR ’best time’:ab,ti OR ’best timing’:
ab,ti OR (start* NEXT/3 therapy):ab,ti
2823933
#3 #1 AND #2 128743
#2 ’human immunodeficiency virus vaccine’/de OR ’human im-
munodeficiency virus vaccine’OR ’human immunodeficiency
virus vaccine’:ab,ti OR ’anti human immunedeficiency’:ab,
ti OR ’anti human immunodeficiency’:ab,ti OR ’anti hu-
man immuno-deficiency’:ab,ti OR ’anti human immune-de-
ficiency’:ab,tiOR ’anti acquired immune-deficiency’:ab,tiOR
’anti acquired immunedeficiency’:ab,ti OR ’anti acquired im-
munodeficiency’:ab,ti OR ’anti acquired immuno-deficiency’:
ab,ti OR ’anti hiv’:ab,ti OR antiretrovir*:ab,ti OR ’anti retro-
viral’:ab,ti OR ’anti retrovirals’:ab,ti OR ’anti retrovirus’:ab,
ti OR haart:ab,ti OR ’aids vaccine’:ab,ti OR ’aids vaccines’:
ab,ti OR ’anti human immunodeficiency virus agent’/de OR
’anti human immunodeficiency virus agent’ OR ’antiretro-
virus agent’/deOR ’antiretrovirus agent’ OR ’highly active an-
tiretroviral therapy’/de OR ’highly active antiretroviral ther-
apy’ OR ’highly active antiretroviral therapy’:ab,ti
149867
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